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A B S T R A C T
Background
Tobacco use in Indigenous populations (people who have inhabited a country for thousands of years) is often double that of the non-
Indigenous population. A disproportionate burden of substance-related morbidity and mortality exists as a result.
Objectives
To evaluate the effectiveness of smoking cessation interventions in Indigenous populations and to summarise these approaches for
future cessation programmes and research.
Search methods
TheCochrane TobaccoAddictionGroup SpecialisedRegister of Trials was searched (April 2011), with additional searches ofMEDLINE
(May 2011). Online clinical trial databases and publication references were also searched for potential studies.
Selection criteria
We included randomized and non-randomized controlled trials for smoking cessation interventions in Indigenous populations. Inter-
ventions could include pharmacotherapies, cognitive and behavioural therapies, alternative therapies, public policy and combination
therapies. No attempts were made to re-define Indigenous status for the purpose of including a study in this review.
Data collection and analysis
Data pertaining to methodology, participants, interventions and outcomes were extracted by one reviewer and checked by a second,
whilst methodological quality was extracted independently by two reviewers. Studies were assessed by qualitative narrative synthesis and
where possible meta-analysis. The review process was examined by an Indigenous (Aboriginal) Australian for applicability, acceptability
and content.
Main results
Four studies met all of the eligibility criteria for inclusion within the review. Two used combination therapies consisting of a pharma-
cotherapy combined with cognitive and behavioural therapies, whilst the remaining two used cognitive and behavioural therapy through
counselling, one via text message support and the other delivered via clinic doctors trained in smoking cessation techniques. Smoking
cessation data were pooled across all studies producing a statistically and clinically significant effect in favour of the intervention (risk
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ratio 1.43, 95%CI 1.03 to 1.98, p=0.032), however following sensitivity analysis a statistically non-significant but clinically significant
effect was observed in favour of the intervention (risk ratio 1.33, 95%CI 0.95 to 1.85, p=NS) .
Authors’ conclusions
A significant health disparity exists, whereby Indigenous populations, a minority, are over-represented in the burden of smoking-
related morbidity and mortality. This review highlights the paucity of evidence available to evaluate the effectiveness of smoking
cessation interventions, despite the known success of these interventions in non-Indigenous populations. Due to this lack of published
investigations, the external validity of this review is limited, as is the ability to draw reliable conclusions from the results. The limited
but available evidence reported does indicate that smoking cessation interventions specifically targeted at Indigenous populations
can produce smoking abstinence. However this evidence base is not strong with a small number of methodologically sound trials
investigating these interventions. More rigorous trials are now required to assist in bridging the gap between tobacco related health
disparities in Indigenous and non-Indigenous populations.
P L A I N L A N G U A G E S U M M A R Y
Can smoking cessation interventions targeted at Indigenous populations achieve smoking abstinence?
In Indigenous populations, rates of smoking have not fallen as they have in the wider communities around them and the associated
health harms are unacceptable. This review of four studies found that published studies evaluating smoking cessation interventions
specifically aiming to reduce and/or stop the use of tobacco in Indigenous people are significantly lacking. The limited evidence
reported in this review does indicate some benefit in these interventions to help Indigenous people stop smoking. However, the change
in attitudes after one study was negative with fewer people ’ready to quit’ after the smoking cessation intervention was completed.
Consideration needs to be given to cultural differences and traditions when tailoring interventions for Indigenous people. Modified or
innovative interventions and careful outcomes research are needed to improve the usefulness of smoking cessation interventions aimed
at Indigenous populations.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
interventions for smoking cessation for Indigenous populations
Patient or population: Indigenous populat ions
Settings:
Intervention: intervent ions for smoking cessat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Interventions for
smoking cessation
Smoking abstinence
Follow-up: 6 to 12
months
Study population RR 1.43
(1.03 to 1.98)
1081
(4 studies)
⊕©©©
very low1,2
97 per 1000 139 per 1000
(100 to 193)
Low
100 per 1000 143 per 1000
(103 to 198)
Attitudes - readiness to
quit
Follow-up: 6 months
Study population RR 1.64
(0.82 to 3.3)
92
(1 study)
⊕©©©
very low1,2
203 per 1000 334 per 1000
(167 to 671)
Low
200 per 1000 328 per 1000
(164 to 660)
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 There was insuf f icient sequence generat ion, allocat ion concealment and blinding across some studies
2 It is possible that due to the nature of these studies some publicat ion bias is occurring with a failure to publish studies that
produce no ef fect
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B A C K G R O U N D
Specific definitions for ’Indigenous’ vary between regions and pop-
ulations. These definitions remain highly contested and are not
always accepted or used (Nettelton 2007). Such examples include
’Aboriginal Australians’ or ’Torres Strait Islanders’ for the Indige-
nous Australian people, ’First Nations’ is sometimes used to de-
scribe the Indian, Metis, and Inuit populations Indigenous to the
United States of America and Canada. ’Native Hawaiians’ is used
for Hawaii’s Indigenous people and ’Tangata Whenua’ or ’People
of the land’ for the M ori of New Zealand (Cunningham 2003).
In an attempt to create consistency, though cognisant of the pref-
erential syntax for populations, the term ’Indigenous’ has been
chosen to encompass participants within this review as it reflects
“the experiences shared by a group of people who have inhabited
a country for thousands of years, which often contrast with those
of other groups residing in the same country for a few hundred
years” (Cunningham 2003). No offence is intended to any group
whose preferred descriptor is not used.
The term ’intervention’ also has the potential to be misconstrued.
The use of the term in the context of this review is “The process of
intervening on people, groups, entities or objects in an experimen-
tal study. In controlled trials, the word is sometimes used to de-
scribed the regimens in all comparison groups, including placebo
and no-treatment arms” (Cochrane Glossary 2011). This term is
not to be confused with the ’Northern Territory Intervention’ of
Australia for example, where the Federal Government acquired
control of local community land leases for a five year period and
removed the permit system that allowed Aboriginal communities
to control access of land. No offence is intended by the use of this
term.
Indigenous populations bear a disproportionate burden of sub-
stance-related morbidity and mortality in comparison to non-In-
digenous populations throughout the world. The prevalence of
tobacco use amongst Indigenous people is often, in fact, double
that of the relevant non-Indigenous population, with estimates of
51-59% in Canada (Health Canada 2003; CEITC 2005), 51%
in Australia (ABS 2006; CEITC 2005), 51% in New Zealand
(Borman 1999; CEITC 2005) and 44% in the United States for
Native Alaskans (First Nations Center 2005; Alaska Department
of Health 2006). One report from Canada suggests that 62%
of First Nation and Inuit people are smokers, with the greatest
smoking prevalence of 74% within their young adults aged 20
to 24 years (CEITC 2005). Similarly, approximately two million
American Indians and Native Alaskans live in the United States
and combined they have the highest prevalence of tobacco use
(32%), among ethnic minorities. Another evaluation of M ori,
Indigenous to New Zealand, suggested that tobacco kills nearly
600 M ori prematurely every year (Reid 1991), with the average
life expectancy of 70.4 years in males compared to 79.0 years for a
non-M ori and 75.1 years compared to 83 years for M ori and
non-M ori women respectively (The Social Report 2010).
Due to cultural and geographic diversity, tobacco use often varies
widely between sub-populations and regions. An increased smok-
ing prevalence may be attributed to a comparatively low socio-
economic status (SES) in Indigenous communities, the ’normali-
sation’ of tobacco use (Harvey 2002), racism (Paradies 2006) and
early introduction of tobacco as a means of payment for services
rendered (Briggs 1996), which may have contributed to a higher
prevalence of tobacco use in some communities. Within Indige-
nous Australian populations, high levels of community acceptance
for smoking has been identified as a barrier in cessation initiatives
for hospital patients (Harvey 2002) and school students (Lowe
2004), since smoking appears to play a key role in social interac-
tion and relationship building (Briggs 2003). In some cases sub-
standard, overcrowded living conditions further increase tobacco
exposure in young people and non-smokers (ABS 2006; DHA
2006). Tobacco cessation interventions which appear effective in
one population will not necessarily work in another. Many In-
digenous tribes in America consider tobacco as a sacred gift and
use it during religious ceremonies and as traditional medicine
(MMWR 2007). As a result of this high smoking prevalence, the
leading cause of death in these communities is cardiovascular dis-
ease (MMWR 2007).
Despite the fact that there is a high prevalence of tobacco smok-
ing in Indigenous populations compared to non-Indigenous pop-
ulations, most research in smoking intervention has occurred in
the latter (Lancaster 2005a; Lancaster 2005b; Rigotti 2007; Rice
2008; Stead 2008; Civljak 2009). The failure of otherwise suc-
cessful population health and individual treatment strategies to
reduce smoking rates in Indigenous settings could be related to ei-
ther access or content. Public mass media information campaigns
may not reach the target audience, may not be linguistically or
culturally appropriate, may not be delivered by an appropriate
representative or may simply be less effective. Even if smoking is
accepted as harmful, it may be relegated behind other concerns
such as other substance abuse problems, levels of education and
issues relating to the criminal justice system. Treatment services
may not reach Indigenous smokers or may be less effective. An
alternate possibility is that there is in fact no difference in program
reach or efficacy and that the ongoing differences in smoking rates
are associated with poverty, unemployment or other aspects of the
social contact of smoking.
Onlymethodical researchwill close this knowledge gap. Systematic
consolidation of interventions and sub-components for those in
this high-risk populace is warranted, to identify features of any
effective programs for Indigenous populations so that they can
be pursued (US Dept Health and Human Services 1998) and
to identify ineffective programs so that they can be altered or
abandoned.
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O B J E C T I V E S
To evaluate the effectiveness of smoking cessation interventions
in Indigenous populations and to summarise these approaches for
future cessation programmes and research.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT) or quasi-randomised con-
trolled trials (CCT).
Types of participants
Participants were young people and adults of any age and either
gender, who were Indigenous to their country and were active
smokers participating in a smoking cessation study. Trial partici-
pants were not required to be selected according to their suscepti-
bility to quitting or suitability for particular interventions. Studies
aimed at pregnant women were also assessed for inclusion even
though this area may be considered highly specialised, since some
of the issues may be common to Indigenous people generally.
No attempts were made to re-define Indigenous status for the
purpose of including a study in this review. Whenmeaningful data
were found which referred to an Indigenous subpopulation in a
larger study, it was assessed for inclusion in the review.
Types of interventions
We included interventions in five categories:
1.) Pharmacotherapies (including nicotine replacement therapies,
bupropion and varenicline tartrate).
2.) Cognitive and behavioural therapies, (including CBT (Cogni-
tive Behavioural Therapy), counselling, support groups, self-help,
seminars, motivational lectures).
3.) Alternative therapies (including acupuncture, hypnotherapy,
aversion therapy).
4.) Public policy (including legislative interventions, media cam-
paigns, community interventions).
5.) Combination therapy (including a combination of at least two
therapies from the above four categories).
We did not exclude trials with high levels of attrition, however this
was documented within the risk of bias tables and discussed.
Controls were assessed as usual practice, no intervention, placebo,
co-interventions (e.g. an intervention such as alcohol cessation
counselling that occurs in both the intervention and control arm)
or reduced intervention. Control participants receiving reduced
interventions could be offered brief advice onquitting, but support
had to be of a lower intensity than that given to the intervention
participants.
Types of outcome measures
Primary outcomes
The primary outcome was smoking cessation as defined by con-
tinuous abstinence and/or the relevant ’point prevalence’ as de-
scribed by the authors, for the longest follow-up point reported
in the study (minimum of six months). The strictest definition
of sustained abstinence was used (e.g. if results were presented as
’no smoking’ or ’smoking < five cigarettes’ throughout the study
period, the data for the ’no smoking’ population was used).Where
possible individual study authors performed biochemically vali-
dation. Trials reporting less than six-months’ follow up were ex-
cluded.
The type of ’smoking’ as defined for this review refers to the prac-
tice where tobacco is burned and the vapours are either tasted or
inhaled (e.g. cigarettes, tailor-mades and rollies).
Secondary outcomes
Secondary outcomes considered for this analysis included:
1. Adverse effects of interventions (through relevant reporting
scales or narrative synthesis)
2. Mortality
3. Costs of interventions
4. Change in quality of life (e.g. St George Respiratory
Questionnaire, SF-36 (Short Form-36), PsyQol (Psychological
Quality of Life) or any other generic quality of life tool)
5. Change in pulmonary function (e.g. FEV¹, FVC etc)
6. Change in attitudes (e.g. readiness to quit)
7. Change in knowledge (e.g. health effects of tobacco)
8. Change in exercise tolerance (e.g. six-minute walking
distance (6MWD))
Search methods for identification of studies
Electronic searches
We identified potential studies from the Tobacco Addiction spe-
cialised Register (April 2011). This was generated through reg-
ular searches of The Cochrane Library, EMBASE, MEDLINE,
PsycINFO and Science Citation Index for trials of smoking cessa-
tion and prevention interventions. No language restrictions were
applied. The following free text search terms were used to identify
records relevant to the topic:
’Aborig*’ OR ’Indigenous*’ OR ’Inuit’ OR ’Maori’ OR ’Native
American’ OR ’American Indian’ OR ’tribe*’ OR ’tribal’
6Interventions for smoking cessation in Indigenous populations (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Online clinical trial registers were also searched for ongoing and
recently completed studies including, Controlled Clinical Tri-
als (www.controlled-trials.com), the National Research Register
(www.nrr.nhs.uk), government registries (clinicaltrials.gov), and
WHO registries (www.who.int/trialsearch/).
For these searches the topic related terms were combined with the
term ’smoking cessation’.
Searching other resources
Reference lists of all included studies and reviews were screened
to identify potentially relevant citations. In addition, enquiries
regarding other published or unpublished studies known to the
authors of the included studies were made.
Data collection and analysis
The entire review process was examined by an Indigenous (Abo-
riginal) Australian for applicability, acceptability and content.
Selection of studies
From the title, abstract, or descriptors, KC independently reviewed
the literature searches to identify potentially relevant trials. All
studies that clearly did not meet the inclusion criteria in terms
of study design, population or interventions, were excluded. KC
extracted the data, which was checked by a second reviewer MB.
Both KC and MB independently extracted data for risk of bias in
all included studies.
Data extraction and management
KCextracted data for the trials using a standardised data extraction
form prior to entry into The Cochrane Collaboration software
program Review Manager 5.1. KC also attempted to correspond
with authors to obtain any missing or raw data as required.
The following information was extracted:
Methods: country/setting of trial, design, objectives, study site,
methods of analysis;
Participants: age, gender, ethnicity, socio-economic status, n-val-
ues for eligibility, recruitment and completion, recruitmentmeans;
Interventions: descriptions of interventions and controls, dura-
tion, intervention delivery, type/dose/duration of pharmacother-
apy or behavioural support, and control group components;
Outcomes: method of outcome collection, pre-specified outcome
data, validation, follow-up period, other followups and definitions
of abstinence, outcome data as defined under ’Types of outcome
measures’ in this protocol;
Risk of bias: methods of sequence generation, allocation conceal-
ment, blinding of participants and outcome assessors, incomplete
outcome data, selective outcome reporting, comparability of in-
tervention and control group characteristics at baseline, imbal-
ances in outcome measures between intervention and control at
baseline, protection against contamination, selective recruitment
of participants, and other potential threats to validity.
Assessment of risk of bias in included studies
Risk of bias (ROB) was evaluated by two independent reviewers,
KC andMB, in line with recommendations made in theCochrane
Handbook of Systematic Review of Interventions (Higgins 2009).
This was on the basis of allocation sequence, allocation conceal-
ment, blinding for participants and outcome assessors, incom-
plete outcome data, selective outcome reporting and other poten-
tial threats to validity. Three additional domains were included to
assess design-specific threats to validity including: imbalances of
outcome measures at baseline; comparability of intervention and
control group characteristics at baseline; and protection against
contamination (EPOC 2009). The risk of bias associated with an
additional domain of selective recruitment of participants was also
assessed. ROB for each domain was assessed as ’low risk’, ’high
risk’ and ’unclear risk’ of bias, as per the guidelines from table
8.5.c of the Cochrane Handbook (Higgins 2009). Conflicts in the
assessments were resolved by consensus.
Measures of treatment effect
Where possible, a risk ratio (RR) was provided for the primary
outcome of each trial. This was defined as (number of subjects
that stopped smoking in the intervention group/ total number
randomised to the intervention group) / (number of subjects that
stopped smoking in the control group/ total number randomised
to the control group). The RR was greater than 1 if more subjects
ceased smoking in the intervention group in comparison to the
control group. An estimated pooled weight average for RRs was
calculated using the Mantel-Hetzel fixed-effect model, with 95%
confidence intervals. In all instances an intention-to-treat analysis
was assessed. For secondary outcomes the differences in change
scores were considered for analysis.
Unit of analysis issues
In the case of cluster controlled trials, analysis was performed at
the level of individual whilst adjustments were made to account
for clustering effects in the data. For studies that did not include
adjustments for clustering, the size of the trial was reduced to the
effective sample size (Rao 1992) using the original sample size
from each study, divided by a design effect of 1.2, which is consis-
tent with other smoking cessation intervention trials (Gail 1992),
and as per recommendations in the Cochrane Handbook, section
16.3.4 (Higgins 2009). We expected trials to use a variety of sta-
tistical methods to investigate or compensate for clustering; we
recorded whether studies used these and whether the significance
of any effect was altered (see Characteristics of included studies).
In the case of multi-arm trials we would have included each pair-
wise comparison separately, but with shared intervention groups
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divided out approximately evenly among the comparators. How-
ever, if the intervention groups were deemed similar enough to be
pooled, the groups would have been combined using appropriate
formulas in the Cochrane Handbook (table 7.7.a for continuous
data and chapter 16.5.4 for dichotomous data) (Higgins 2009).
Dealing with missing data
Missing information regarding participants was evaluated on an
available case analysis basis as described in chapter 16.2.2 of the
CochraneHandbook (Higgins 2009).Missing standard deviations
would have been addressed by imputing data from the studies
within the same meta-analysis or from a different meta-analysis
as long as these used the same measurement scale, had the same
degree of measurement error and the same time periods, (between
baseline and final value measurement), as per chapter 16.1.3.2
of the Cochrane Handbook (Higgins 2009). Where statistics es-
sential for analysis were missing (e.g. group means and standard
deviations for both groups were not reported) and could not be
calculated from other data, attempts were made to contact the
authors to obtain data. Loss of participants that occurred prior
to performance of baseline measurements were assumed to have
no effect on the eventual outcome data of the study. Any losses
after the baseline measurement were taken, have been assessed and
discussed. Subjects lost to follow up were assumed to be smoking
and were included in the denominators for calculating the relative
risk, as per standard Tobacco Addiction Group methods.
Assessment of reporting biases
Providing the inclusion of greater than ten included studies, po-
tential reporting biases would have been assessed using a funnel
plot. Asymmetry in the plot could have been attributed to publica-
tion bias, but may well be due to true heterogeneity, poor method-
ological design or artefact. In case of asymmetry, we could have in-
cluded contour lines corresponding to perceivedmilestones of sta-
tistical significance (p=0.01, 0.05, 0.1etc.) to funnel plots, which
may help to differentiate between asymmetry due to publication
bias from that due to other factors (Higgins 2009). In instances
of fewer than ten studies, the reporting biases were extrapolated
within the ’other bias’ section in the risk of bias tables.
Data synthesis
Qualitative narrative synthesiswas performed for all included stud-
ies in addition to meta-analysis (see Measures of treatment effect
for details about meta-analysis). Subjective (rather than statistical)
methods were used to compare the study outcomes using a stan-
dardised template for extraction by one reviewer (KC), which was
checked by a second (MB). The narrative synthesis of evidence was
reported in a table format separated for the pre-specified primary
and secondary outcomes (see: Types of outcome measures).
Subgroup analysis and investigation of heterogeneity
We attempted to categorise trials according to the subgroups listed
in Types of interventions above. Consideration was given to pool-
ing trials within these subgroups, however insufficient studies did
not permit subgroup analysis. Had there been sufficient numbers
of included studieswewould have attempted topool trials of differ-
ent pharmacotherapies, trials of different intensities of behavioural
interventions, or different types of population based interventions
within subgroups under each category.We considered the addition
of further heterogeneity contributed by factors such as baseline
smoking status, participant and community characteristics, (e.g.
age, physical state, cultural and educational differences), time of
measurement of results and varying measurement tools used to as-
sess outcomes. The chi square and I² statistic (Higgins 2009) were
used to quantify inconsistencies across studies. In groups of trials
where meta-analysis is judged potentially appropriate, extracted
data were pooled using the fixed-effect model. In the presence of
significant heterogeneity (as defined by: I² > 60%, visual inspec-
tion of study data and consideration of study design and method-
ology), the use of a random-effects model would have been con-
sidered. However this would have been considered with caution
taking into account the possible influence of smaller studies which
could over or under estimate the true treatment effect. To consider
instances where meta-analysis may not be judged appropriate, we
also used narrative synthesis, treating the studies individually with
consideration of their confidence intervals. Providing sufficient
numbers of included studies we would have considered reporting
the results restricted to the larger, more rigorous studies as sug-
gested in section 10.4.4.1 of the Cochrane Handbook (Higgins
2009). These data were all analysed using Review Manager 5.1.
Ideally we aimed to conduct subgroup analyses for each popula-
tion (e.g. Aboriginal Australian, Native Alaskan etc). Also within
each population, we considered that smoking prevalencemay vary
widely between dispersed community groups, further adding to
potential heterogeneity of results. As each Indigenous population
is unique and each has specific characteristics (such as remote-
ness) that could influence the effectiveness of smoking cessation
interventions, subgroup analysis would have provided the most
relevant results for a particular population. However insufficient
studies meeting the inclusion criteria existed for any populations
to be analysed as a subgroup.
Subgroup analysis of remote versus urban dwelling and isolated
versus integrated populations would also have been considered.
Providing sufficient studies existed we would have also performed
a subgroup analysis for cessation initiatives in young people (aged
<25 years) and pregnant women.
In studies of long duration, we considered that results may be
presented for several periods of follow-up including short-term (<
26 weeks), medium-term (27 to 52 weeks) and long-term (> 53
weeks). Data permitting, extended follow up would also have been
collated for studies presenting data over two years.
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Sensitivity analysis
Sensitivity analysis was conducted on studies with a high risk of
bias for sequence generation and/or allocation concealment and
studies with participants with significant co-morbidities.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The literature search retrieved 292 references after duplicates were
removed, with 43 references identified from this search for retrieval
and possible inclusion in the review. Five studies were obtained
from the bibliographies of retrieved articles, one of which was
later identified as a study for inclusion. From these, four trials (six
publications) were identified for inclusion in the review (see Figure
1), with seven trials identified as potential ongoing studies (eight
publications) (Characteristics of ongoing studies).
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Figure 1. Study flow diagram.
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Included studies
The four studies included in this review were published between
1997 and 2005. Two were randomised controlled trials (Bramley
2005a; Holt 2005) and the remaining two studies used a con-
trolled clinical trial design. Holt 2005 and Ivers 2003 investigated
pharmacotherapy for smoking cessation (bupropion and nicotine
replacement therapy respectively) in addition to some form of
counselling. The Bramley 2005a study used a randomised inves-
tigation of smoking cessation services through mobile phone text
messaging, whilst the Johnson 1997 study used a ’Doctors Help-
ing Smokers’ model where doctors and clinical staff were trained
in smoking cessation and counselling techniques. For full details
of each trial see Characteristics of included studies.
A total of 1201 subjects were included from these four studies. Two
were based on theM ori population Indigenous to NewZealand
(Bramley 2005a; Holt 2005), one on Aboriginal Australians and
one on American Indians. Overall follow-up time periods ranged
from six to twelve months post baseline data collection, although
intermediate data collection also occurred in two studies (Bramley
2005a; Holt 2005), and ranged from three weeks to nine months
(Holt 2005) post intervention commencement. Intervention du-
rations were seven weeks, ten weeks and six months for the Holt
2005, Ivers 2003 and Bramley 2005a studies respectively, whilst
the Johnson 1997 study had two days of training for doctors and
clinical staff with no data provided on intervention duration re-
ceived by patients. Sample sizes were medium to large for all stud-
ies with 111 participants in the Ivers 2003 study, 134 in the Holt
2005 study, 355 in the Bramley 2005a study, whilst the Johnson
1997 study had a large total sample size with 601 subjects.
Excluded studies
Twenty-five studies were excluded for the following reasons: no
control group (n=14), no baseline data/smoking related outcome
data presented (n=5), follow-upperiods less than sixmonths (n=2),
not and Indigenous specific population as defined for this review
(n=2), results not reported separately for Indigenous people (n=1)
and no smoking cessation intervention occurred (n=1). See also
Characteristics of excluded studies for more details.
Risk of bias in included studies
The key features for risk of bias in the four included studies are
summarised in Figure 2, in addition to the ’risk of bias’ tables at
the end of each Characteristics of included studies table. Overall
the methodological quality of the studies were good, although
each study had at least one category marked as a high risk of bias.
Agreement for assessment of study quality were reached by two
independent reviewers (KC and MB).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Sequence generation
Sequence generation was a high risk of bias in two studies which
did not randomise subjects (Johnson 1997; Ivers 2003) and low
risk of bias for the remaining two studies, which used a central
telephone randomisation algorithm (Bramley 2005a) and a com-
puter generated code (Holt 2005).
Allocation concealment (selection bias)
Allcoation concealment was unclear in one study (Holt 2005), a
high risk of bias in two (Johnson 1997; Ivers 2003) and a low risk
of bias for the Bramley 2005a study, which used central telephone
randomization with sequence concealment until the intervention
was assigned.
Blinding of participants (performance bias)
Due to the nature of the three community level interventions in
the Johnson 1997, Bramley 2005a and Ivers 2003 studies it was
not possible to blind participants. However the Holt 2005 study
design incorporated a double-blind (i.e. participant and outcome
assessor) design through the use of placebo pills for the control
population.
Blinding of outcome assessors (detection bias)
Both the Bramley 2005a and Holt 2005 studies report blinding of
outcome assessors, whilst this category was unclear in the Johnson
1997 and Ivers 2003 studies with no mention of attempted blind-
ing.
Incomplete outcome data (attrition bias)
Three studies adequately addressed incomplete outcome data in
their analyses with subjects lost-to-follow up being considered as
’continuing smokers’ for outcome data. Secondary analysis mod-
els within the Bramley 2005a study also evaluated data with sub-
jects lost-to-follow-up as non-smokers as per their pre-specified
analysis plan. The Johnson 1997 study had a high risk of bias, as
response rates for subjects in Seattle were significantly lower (p=
0.002) compared to the other three health centres, resulting in a
higher proportion of assumed-to-be-smokers.
Selective reporting (reporting bias)
Selective reportingwas not identified in any of the included studies
with a low risk of bias for each inclusion.
Imbalance of outcome measures at baseline
Three studies had low risks of bias for imbalances in outcomes
measures at baseline with two studies (Johnson 1997; Bramley
2005a) conducting analysis of covariance and another study (Holt
2005) presented all of their baseline data with no imbalances re-
ported. The Ivers 2003 study reported statistically significant dif-
ferences between intervention and control participants at baseline.
There was no mention of statistical adjustments made within the
publication to account for these differences.
Comparability of intervention and control group
characteristics at baseline
Similar to ’imbalances in outcome measures at baseline’, the com-
parability of intervention and control group characteristics at base-
line was a low risk of bias for three studies which reported their data
and was found to be similar across groups (Johnson 1997; Bramley
2005a; Holt 2005). The Ivers 2003 study however demonstrated
statistically significant differences between intervention and con-
trol groups at baseline, with no mention of adjustments incorpo-
rated within analysis models.
Protection against contamination
Potential contamination was a low risk of bias in three studies
(Johnson 1997; Ivers 2003; Holt 2005) and an unclear risk of
bias in one study (Bramley 2005a). For the Bramley 2005a study,
author’s mention that no restrictions were placed on the use of
other smoking cessation strategies. To clarify, they mention that
this trial was designed to test the addition of mobile phone-based
services to existing practice. No further information was provided
regarding any confirmed contamination.
Selective recruitment of participants
Selective recruitment was a low risk of bias in two studies which
reported n-values and methods of recruitment across groups, and
were deemed similar for intervention and control populations (
Bramley 2005a; Holt 2005). However for the Ivers 2003 study
subjects could ’self-select’ to be in either the intervention or control
group, whilstmethods of recruitment were unclear for the Johnson
1997 study.
Other bias
All four studies had other biases identified which resulted in a
unanimous high risk of bias for this category. The Bramley 2005a
study provided incentives of free text messaging for a month in the
control population only, which authors believemay have increased
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the motivation within the control to report abstinence. It is a pos-
sibility that some of the control participants believed that in order
to receive the month of free text messaging they were required to
report abstinence. As such the control populationmay have had an
advantage over the intervention with increased motivation to quit
as a result of the incentive, and may also have reported false ab-
stinence rates (salivary cotinine validation only occurred in a sub-
set of participants). In the Holt 2005 trial the targeted population
sample size of n=141 were not collected due to a lack of eligible
subjects. Authors also point out concerns over generalisability as
the population, through self-selection to participate in a cessation
trial, were highly motivated to quit. The pre-specified study de-
sign in the Johnson 1997 trial was not possible due to funding
limitations. This resulted in an amendment from fourteen study
sites to a total of four (two in each arm). Authors also raised some
concerns over comparability of each of the four clusters due to
significant variations in tribes attending each of the health clin-
ics. Finally the Ivers 2003 study provided no adjustments for po-
tential clustering effects to their data, which was required due to
recruitment from three communities. Authors also report that no
participant complete a full course of nicotine patches, with the
mean number used being five. Only six subjects reported using
more than seven patches (full course of patches for this trial would
have been 70 patches over a 10-week period).Moreover, validation
of smoking was not possible in 18% of intervention subjects and
20% of control subjects.
Effects of interventions
See: Summary of findings for the main comparison
interventions for smoking cessation for Indigenous populations
See also Summary of findings table 1 for the main comparison:
Smoking cessation interventions for Indigenous populations.
Smoking behaviour
Four different interventions were available for evaluation of smok-
ing cessation strategies for Indigenous populations. Three inter-
ventions produced statistically non-significant but clinically signif-
icant effects in favour of the intervention (Johnson 1997; Bramley
2005a; Holt 2005), whilst one study produced a statistically and
clinically significant effect in favour of the intervention (Ivers
2003), however the sample size was small with six intervention and
one control subject reporting abstinence at follow up. Three stud-
ies assessed abstinence through point prevalence (Johnson 1997;
Ivers 2003; Bramley 2005a) and the remaining one via continuous
abstinence. When combined onto the one forest plot to examine
the overall effect, a pooled risk ratio (RR) of 1.43 (95% CI 1.03 to
1.98, p=0.032) is produced in favour of the intervention (Analysis
1.1). However, due to the substantial methodological limitations
including the limited uptake of the intervention found in the Ivers
2003 study (only six subjects usedmore than seven patches, result-
ing in only 10%of the recommended treatment course being com-
pleted), a sensitivity analysis was performed excluding this study
from the meta-analysis. The remaining three studies when pooled
produced a statistically non-significant but clinically significant
effect in favour of the intervention (RR 1.33, 95%CI 0.95 to 1.85,
p=NS) (Analysis 1.3). For the purpose of this review the final fol-
low up period reported in each study has been used for the meta-
analysis. Data in the Johnson 1997 and Ivers 2003 studies were
manually adjusted for potential clustering effects according to the
pre-specified methodology as outlined in Unit of analysis issues
under Methods in this review. The result for both studies were
the same pre-cluster adjustment with a statistically non-significant
but clinically significant effect in favour of the intervention for
the Johnson 1997 study and statistically and clinically significant
effect in favour of the intervention for the Ivers 2003 study. For
a more detailed description of study outcomes see Table 1 which
provides a narrative synthesis of intervention effectiveness.
Adverse events
Adverse events were discussed in two studies with authors in the
Holt 2005 study reporting side effects due to bupropion as mild
and self-limiting. Subjects in the treatment arm were more likely
to experience insomnia (26% versus 9%), over that of the placebo
arm. Three subjects reported a rash in the intervention arm and
ceased treatment as a consequence. Subjects in the Ivers 2003
study were not blinded, as a result adverse events are only re-
ported for the intervention population. Adverse events included
bad dreams (29%), pruritis (21%), nausea (4%), palpitations or
shakiness (7%) and tiredness (7%). Seven percent of subjects re-
ported that the patches would not remain stuck to their skin.
Mortality
One subject in the Ivers 2003 evaluation died during the study
period of causes unrelated to the use of the nicotine replacement
therapy patch.
Costs of interventions
Authors in the Ivers 2003 study evaluated the costs of the interven-
tion (nicotine patches) compared to cigarette smoking. They esti-
mated that a week’s supply of nicotine patches cost approximately
$32-35 in addition to freight costs, in comparison to a pack a day
smoker which can range between $46-74. As a result they com-
ment that other factors apart from the costs of nicotine patches ap-
pear to prevent smokers from using nicotine replacement therapy
as an aid to quitting, which may include a widespread perception
that smoking was normal behaviour.
Change in quality of life
No included studies addressed this outcome.
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Change in pulmonary function
No included studies addressed this outcome.
Change in Attitudes
One study assessed changes in attitudes through the outcome
’readiness to quit’ (Ivers 2003). Using the Fisher’s Exact test no
significant changes for intervention or control groups were found
(p=1.0 and 0.21 respectively). There was a potentially negative
finding following the intervention, in that 38% of smokers in the
intervention group and 29% in the control group were less ready
to quit after trying patches than they had been at the baseline visit.
Change in knowledge
No included studies addressed this outcome.
Change in exercise tolerance
No included studies addressed this outcome.
D I S C U S S I O N
Summary of main results
Four completed studies assessed the benefits of smoking cessa-
tion interventions for Indigenous populations in 1201 subjects,
(two studies in New Zealand (M ori), one in Australia (Abo-
riginal) and one in the United States of America (American In-
dian)). Whilst some methodological variations occurred between
studies in relation to intervention, delivery, mode of action and
duration, they all were aimed at smoking cessation. In pooled
analyses, a statistically and clinically significant effect in favour of
the intervention was evident for the primary outcome of smok-
ing cessation (RR 1.43, 95%CI 1.03 to 1.98, p=0.032), however
following sensitivity analysis and removal of one study, a statisti-
cally non-significant but clinically significant effect was observed
(RR 1.33, 95%CI 0.95 to 1.85, p=NS). Only one study examined
changes in attitudes potentially demonstrating a negative finding,
in that intervention subjects were less ready to quit following the
intervention (see also Summary of findings table 1). This may be
attributed to the recent failed smoking cessation attempt affect-
ing confidence and motivation, subsequently reverting the sub-
ject back through the trans-theoretical model (Prochaska 1988)
into the pre-contemplation phase. Adverse events were discussed
in two studies with one reporting a statistically significant increase
in episodes of insomnia for the intervention arm of bupropion,
over that of placebo. The remaining study reported adverse events
for the intervention arm only (nicotine patches), with the most
common adverse event being bad dreams experienced in 29% of
the intervention population. Costs of interventions were assessed
in one study with authors commenting that other factors exclud-
ing costs of nicotine patches must prevent smokers from using
this cessation aid, as the cost of patches in comparison to the esti-
mated costs of a pack-a-day smoker is lower. One study reported
mortality with only one subject dying during the study period, for
reasons unrelated to the trial.
Overall completeness and applicability of
evidence
In the context of current practice, this review should be used to
provide readers with an outline of what interventions have proven
effectiveness, and where resources need to be directed for future
investigations. However, the limited number of included studies
and small samples sizes of these trials does limit the ability to draw
reliable conclusions from the results. As such, interpretation of
these findings need to be considered with caution. The overall
completeness and applicability of the evidence found it this review
highlights the paucity of data that exists to evaluate smoking cessa-
tion interventions for Indigenous populations around the world.
Successful campaigns identified in this review have surveyed and/
or conducted pilot investigations in the population being targeted
and then tailored an appropriate intervention which meets the re-
quirements of the communities needs. Based on the limited evi-
dence from the available studies, a multi-faceted approach which
provides cessation and prevention from various sources simultane-
ously, in addition to promoting community engagement, appear
more likely to be successful in the reduction and cessation of smok-
ing. Importantly, evaluations need to be performed alongside any
future smoking cessation programs to ensure the applicability and
effectiveness of the intervention not only for the targeted commu-
nity, but also for the translation of evidence both nationally and
internationally. To ensure intervention effectiveness and method-
ological rigour, future interventions should aim to incorporate the
following into the study design:
• Use culturally appropriate interventions tailored for the
population being targeted; consider the views and incorporate
the suggestions of key members from the population (develop
the intervention with community members); provide sufficient
intervention exposure, duration and training; where possible
involve Indigenous health care workers or project officers for
intervention delivery and outcome collection
• Ensure an adequate control group which mirrors the
demographic characteristics of the intervention population;
consider potential sources of contamination where the
intervention may reach the control population and incorporate
strategies to minimise this risk
• Data collection (including smoking status) needs to occur
pre-intervention and post-intervention in the same cohort of
subjects; provide meaningful follow-up periods (i.e. minimum
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six-months post-baseline data collection); outcome data and
methods of analysis should be pre-specified to reduce post hoc
amendments and additions which can introduce bias; calculate a
target sample size prior to recruitment which has sufficient
power to determine intervention effectiveness
Quality of the evidence
A significant health disparity exists whereby Indigenous popula-
tions, a minority, are over-represented in the burden of smok-
ing-related morbidity and mortality (Bramley 2005b; ABS 2006;
Wood 2008). Despite this, a paucity of evidence using method-
ologically rigorous evaluations to assess smoking cessation inter-
ventions has been identified for the Indigenous population, which
has been confirmed by many researchers (Gray 2000; Gohdes
2002; Ivers 2003; Clifford 2009). As a result, the external valid-
ity of this review is limited by a lack of published investigations
on which to draw a conclusion. Not only is there a lack of evi-
dence examining the different types of interventions (e.g. phar-
macological, behavioural etc.), there is also a lack of investigation
for the various sub-sets of Indigenous populations (e.g. Native
Alaskan, M ori, Aboriginal Australian, American Indian etc.).
Of the available data, study quality is a potential issue with some
studies in this review being of unclear methodological quality or
of a high risk of bias. There are no cost-effectiveness studies for
dissemination of smoking cessation interventions, that are spe-
cific to Indigenous health-care services and programs. The gap
in this evidence has also been identified in other recent studies
(Sanson-Fisher 2006; Clifford 2009), and is of concern due to the
gap in health disparities between Indigenous and non-Indigenous
populations, which are further exacerbated by the delay between
intervention research efforts and implementation of cost-effective
dissemination strategies (Berwick 2003).
Of note, no methodologically rigorous evaluations alongside gov-
ernmental policies were identified for this review despite the large
monetary investments publicised for Indigenous smoking ces-
sation strategies (Ministry of Health 2004; COAG 2009; SA
Department of Heatlh 2010; US Dept of Health and Human
Services 2010). These policies (which can includemassmedia cam-
paigns, access to free nicotine replacement therapies etc.) require
considerable resources, however their subsequent efficacy to in-
crease long-term smoking abstinence following implementation is
unknown. The use of such resources for programs with unproven
effectiveness in the Indigenous context can have a detrimental
result, as resources provided for the delivery of ineffective inter-
ventions means an opportunity cost for other interventions (Ivers
2004). One concern is that epidemiological studies have reported
that tobacco control infrastructures (e.g. outreach smoking cessa-
tion clinics or public policy initiatives) vary or are lacking between
communities despite the implementation of wide-spread policies
(Baezconde-Garbanati 2007; Johnston 2010b). The reasons for
this are not widely understood, though some researchers hypothe-
sise that the historical and cultural role that tobacco plays in these
communities in addition to the sovereignty of tribal nations (par-
ticularly for American Indians), may result in these policies not be-
ing implemented within the communities (Baezconde-Garbanati
2007). Other suggestions relate to the lack of enforcement of ex-
isting tobacco legislation, reticence by the community to change
the status quo and few non-smoking role models in leadership
positions (Johnston 2010b). As such, the next phase in tobacco
cessation strategies for Indigenous populations must include ac-
companying assessments to determine the success of the interven-
tion, efficacy of its implementation and ability for mass-dissem-
ination. This does not necessarily dictate that a heavily funded
double-blind randomized controlled trial is required. Rather, an
assessment involving descriptive and qualitative data to determine
the likely success following the transfer of interventions to the In-
digenous setting may suffice (Ivers 2004).
Potential biases in the review process
A potential bias in the review process is exclusion of studies ex-
amining Indigneous specific interventions that are of question-
able methodological design. This review does sacrifice inclusion of
some relevant information, however the trade-off is a meta-anal-
ysis of higher quality evidence on which future investigations can
be based. Some of the pertinent information from these studies
are discussed below under ’Agreements and disagreements with
other studies or reviews’ though results should be interpreted with
caution. One key strength of the review process to address poten-
tial biases, is the use of two experienced and independent review
authors who assess the study quality. Although this can do little to
account for biases which occur in the methodological designs of
the included studies.
This review of studies does not take into account the social con-
struct of smoking in Indigenous communities and how this differs
from the mainstream dominant culture’s views of tobacco use. It is
difficult to separate addiction from social determinants of tobacco
use, especially for the studies predominantly reporting interven-
tion outcomes. Literature has been published around why Indige-
nous people smoke, with one publication reporting that Aborig-
inal and Torres Strait Islander communities nominate many of
the same reasons for smoking as non-Indigenous Australians in-
cluding, a consolation in bad times, an aid to relaxation and as
a dependable aspect of daily routines (Carter 2001). Another re-
port funded under the National Tobacco Strategy in Australia also
found the most commonly reported reasons for smoking were to
alleviate stress, social considerations, alleviate boredom, routine
habit, used as a ’time out’, and addiction (Lindorff 2002). A close
connection between tobacco used and other social behaviours such
as alcohol, gambling or having a cup of tea or coffee were also
observed (Scollo 2008). Tobacco use is also viewed by some as a
’lesser evil’ being an acceptable alternative to other drugs such as
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alcohol, cannabis and intravenous drugs (CEITC 2005). This is
similar to reports in American Indian communities with smoking
described as a way for women in particular to care for themselves
in response to multiple stressors and responsibilities including the
management of stress, anger and coping with the demands of chil-
dren work and family (Burgess 2007).
Agreements and disagreements with other
studies or reviews
Many studies point out the importance of tobacco use in the cul-
tural and spiritual context of Indigenous populations (Brady 2002;
Daley 2006; Daley 2009), such as with American Indian com-
munities and tobacco’s role in ceremonial, religious and medici-
nal functions (Baezconde-Garbanati 2007). Some of these cultural
practices include burial offerings, spiritual protection or use as a
gift to the Creator, or as a gift to honour someone (Rhoades 2000;
Eichner 2010; Daley 2011). For American Indians in particular
tobacco use has a long and complicated history, with its early use
for ceremonial and therapeutic means, and later cultivation and
trade with European settlers (Rhoades 2000; Eichner 2010). On
a similar note, historical evolution of tobacco in the Indigenous
Australian setting stems from its use as part of government ra-
tions, as a means of payment for services (Briggs 1996; Johnston
2010b), and as one report suggests, to pacify and exploit the In-
digenous owners of the land (Brady 2002). Tobacco has a deep-
rooted history in many Indigenous settings, however it is impor-
tant to realise that current health inequalities do not exist because
of traditional tobacco use, but rather through the abuse of tobacco
(Eichner 2005).
A study of American Indians in the Northern Plains found that
Indian smokers were more likely to report quit attempts of one
or more days in the preceding year, than non-Indians with 67%
compared to 43% respectively (Gohdes 2002). However, actual
quit ratios in this study were lower among Indians with 43%
compared to non-Indians with 65%. Two other recent studies
produced similar results with survey data indicating that a large
proportion of the population were open to interventions aimed
at modifying their smoking behaviour, though no interventions
were easily accessible (Clough 2009). Importantly, the authors of
the investigation state that expecting smokers to quit on their own
without the necessary support is unreasonable and needs to be
provided if smoking abstinence is expected (Clough 2011). This
indicates that it is not necessarily a lack of motivation preventing
abstinence, but rather a lack of means to produce a sustained
benefit. Despite the scarcity of methodologically rigorous studies
existing for inclusion in this review, some limited information
is available for interventions of smoking cessation in Indigenous
populations by means of focus groups, surveys, small pilot projects
and non-controlled trials, which are described below.
As the aim of this review is to examine the broad construct of
tobacco cessation interventions for Indigenous populations world
wide, the information produced is drawn from different Indige-
nous groups. The constant interchange between these populations
may falsely imply that characteristics reported are homogenous
to all Indigenous people. Attempts have been made to limit false
implications in the review.
Summary of evidence for intervention effectiveness in other
published studies:
Pharmacotherapy:
An epidemiological investigation of pharmacotherapy in remote
Indigenous Australian communities identified that of 133 partic-
ipants, 40% (n=53) did not know anything about pharmacother-
apies for smoking cessation, 47% (n=62) knew about them but
had never used them, leaving only 14% (n=18) who had who
had tried some form of pharmacotherapy (Clough 2009). Another
survey in the Indigenous Australian community found that 6 out
of 25 people had used nicotine replacement therapy and two had
been successful in short-term abstinence (Johnston 2010b). Over-
all however, other published evidence for use of pharmacothera-
pies in Indigenous settings is low (Thornley 2010), with associated
costs and availability being concerns highlighted by health care
staff (Johnston 2010b), and lack of information about tobacco
dependence by health care providers, a concern identified by some
Indigenous people (Burgess 2007). Another obstacle identified in
numerous studies is the poor compliance rate with people not re-
turning to clinics to refill prescriptions or reduced supplies when
pharmacotherapy was shared with other family members (Ivers
2003; Johnston 2010b). Some studies have identified cultural spe-
cific barriers to the use of pharmacotherapy, including lack of trust
in conventionalmedicine related to historic and continuing racism
(Burgess 2007), and some participants in the included Ivers 2003
study reported bad dreams or nightmares. This is particularly im-
portant for Aboriginal Australians as dreams signify that a person
is being ’sung’ to, or cursed, which consequently produces reti-
cence for the uptake of pharmacotherapy community wide.
Cognitive and behavioural therapies:
In remote Indigenous communities, brief interventions, advice,
support services and counselling for smoking cessation are not rou-
tinely available, or are based in regional centres which are under-
resourced or inappropriately targeted (Briggs 2003, Ivers 2003,
Baker 2006, Clough 2009). Community support and small group
counselling sessions have the potential to boost quit rates, however
intrinsic and explicit pressures to maintain smoking behaviours
exist. Examples of barriers described by Aboriginal Australians
attempting to quit in one survey include: being asked to buy
cigarettes for family, continued offers of cigarettes by friends and
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family and the feeling of isolation and exclusion from social gath-
erings where people were smoking (Johnston 2010b). One study
comparing the relationship between tobacco use and cardiovascu-
lar disease in an American Indian population, found that a greater
proportion of smokers who had a co-morbid condition such as
diabetes, hypertension or renal insufficiency quit smoking, com-
pared to those without a co-morbid condition (Eichner 2010).
Another survey in Aboriginal Australians identified that interven-
tions delivered in the primary health care setting were ineffective
unless associated with a major health event (Johnston 2010b). In
Johnston 2010b, drivers to keep smoking such as social pressures,
addiction and stress outweighed motivations to quit.
Alternative therapies:
No evidence was available in any of the published literature for al-
ternative therapies directed specifically at Indigenous populations.
Public policy:
Public policies for smoke-free areas and homes when initiated by
individuals, do not appear to produce the associated barriers to im-
plementation seen in some of the other interventions. For exam-
ple, the alteration in attitudes and display of ’smoke-free’ stickers
on verandas and houses in an Aboriginal Australian community
trial testifies to this (Johnston 2010b). The health protection of
children was the argument most often used in support of smoke-
free areas for this survey and appeared to generate the most trac-
tion in producing a consensus on the tobacco issue. In summary,
the survey identified that community implemented public policy
which highlights the importance of a ’smoke-free environment’ for
youth, would likely be an effective motivator for smoking cessa-
tion in adults. However, no methodologically rigorous trials sup-
porting this claim have been identified to date.
Increasing the taxes on tobacco as a disincentive to smoke in In-
digenous communities need to be considered with caution. One
study survey produced an alarming result with subjects priori-
tising tobacco over food or paying bills for amenities (Johnston
2010b). Nonetheless, when funds were scarce, changes in smok-
ing behaviour did occur with subjects using alternative strategies
including asking family for cigarettes, purchasing tobacco from
the black market or rolling cigarettes from the tobacco remaining
in discarded butts (Johnston 2010b). Another study suggests that
taxation of tobacco could have substantial health and economic
benefits, however governments and other organisations need to
examine such policies in the context of Indigenous populations,
with consideration for cultural appropriateness (Wardman 2005).
One excluded study assessing the ‘Bubblewrap’ mass media cam-
paign reported that significantly more subjects recalled aware-
ness of television advertisements over that of radio. This program,
though of minimal impact for sustained smoking cessation with
1.5% successfully quitting after two months, did result in a quar-
ter of smokers attempting cessation and over 30% reporting that
they had cut down the number of cigarettes consumed to some
degree (Boyle 2010). Another similar study piloted in Indigenous
Australians found good recall of mainstream anti-tobacco media
messages among community members, however both Indigenous
and non-Indigenous staff perceived that the marketing campaign
needed to be significantly modified to be socially acceptable to an
Indigenous audience (Johnston 2010b).
Combination therapies:
The majority of studies falling into the above categories could be
classified as combination therapies as they include intervention
messages delivered via multiple sources. Examples include when
pharmacotherapy is prescribed or delivered via a health care pro-
fessional as some form of accompanying behavioural intervention
is usually provided.On amore expansive note, one study suggested
that lifestyle brief interventions need to be coupled with multi-
level health strategies, as the potential effectiveness will be lim-
ited in the absence of broader strategic objectives aimed at com-
munity-identified health priorities such as alcohol and other drug
abuse (Harvey 2002). Another study reports similar findings in
that the capacity to effectively address the disproportionate burden
of tobacco-use is contingent upon the presence of multiple sources
of program message delivery, appropriate distribution of funds
and resources and an underlying understanding of community
strengths, history, values and participation (Baezconde-Garbanati
2007). A third study assessing cancer-related health behaviours
among Inuit residents in Canada’s north, found that lower health
service utilisation and health-related behaviours leading to in-
creased cancer risk (e.g. tobacco use), appear to be due to unob-
served factors specific to their unique social-cultural context. As
such they also recommend that policy interventions designed to
address these problems be specifically targeted for the population
and should not be considered in isolation of their broader health,
economic and social environment (McDonald 2010). However
these multi-level strategies are yet to be tested in the Indigenous
population under high methodological design standards and as
such no strong evidence is available to confirm that such an ap-
proach would be any more or less effective in the context of to-
bacco control interventions.
Summary of evidence for intervention effectiveness in other
systematic reviews:
One systematic review which assessed behavioural smoking ces-
sation interventions for disadvantaged groups devoted one sec-
tion of the evaluation to Indigenous populations (Bryant 2011).
They identified two studies targeted at Indigenous smokers (one of
which, Bramley 2005a, was incorporated into this review); how-
ever pooled analysis produced no statistically significant effect (RR
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1.34, 95%CI 0.91 to 1.96). These findings are almost identical
to the pooled estimate of smoking cessation found in this review
following sensitivity analysis (RR 1.33, 95%CI 0.85 to 1.85) and
both reviews report similar clinical significance. The authors of
the Bryant 2011 systematic review also concluded that further re-
search is required that is adequately funded and powered to estab-
lish the most effective cessation intervention.
Another systematic evaluation aimed at the review of efforts to in-
crease the uptake of evidence-based interventions in Indigenous-
specific health care settings and programs also identified two stud-
ies related to smoking for inclusion (Clifford 2009). Authors of
the review suggest that the use of outcome measures with demon-
strated reliability and validity to quantify the effect of interven-
tions are required to evaluate changes in health service delivery,
and would improve methodological rigour by almost 50% in In-
digenous dissemination strategies (Clifford 2009).
Similar to conclusions in this meta-analysis, a 2009 review of to-
bacco interventions in Aboriginal Australians found evidence that
nicotine replacement therapy and/or counselling, specifically tar-
geted at individuals may be an effective smoking cessation aid,
however results were only reported through narrative synthesis
(Power 2009). A review of tobacco interventions conducted by
Ivers et.al in 2003 found a major lack of research evaluating to-
bacco interventions for Indigenous Australians (Ivers 2003). Al-
though the four included studies reported in that review were not
the same as the evidence utilised in this meta-analysis, the message
produced concerning the lack of evidence in spite of the significant
health disparity is the same.
Smoking cessation in pregnant women:
Rates of smoking in Indigenous pregnant women have been re-
ported as high, as 50 to 65% (Eades 1999; Mohsin 2005; Laws
2006; Laws 2008). It iswell known that smokingduringpregnancy
can have devastating health consequences not only on the mother
but also the unborn child (Horta 1997; Horta 2001; Wills 2008).
Early research in Indigenous women has associated smoking with
an increased risk of sudden infant death syndrome (Bulterys 1990;
King 1997). Despite this, only limited evidence currently exists to
examine interventions for smoking cessation specifically designed
for Indigenous pregnant women (Pullon 2003;Wills 2008; Wood
2008; Panaretto 2009), of which no investigations were of suf-
ficient quality to be included within the analyses of this review.
The closest evidence available to assess this sub-group has been
identified in one ongoing study protocol (Johnston 2010a), which
will assess environmental tobacco smoke exposure on Indigenous
pregnant women and their children as a primary outcome.
Challenges to consider:
Some potential implementation barriers for smoking cessation
programs were identified in a brief intervention piloted in three
routine clinical practice cites (Harvey 2002). These should be
considered when planning future investigations and include: con-
straints surrounding the intervention training program and em-
bracing the needs of a diverse workforce, issues concerning long-
term sustainability and the uptake of changes in clinical prac-
tice and the subsequent difficulties associated with introduction
of new ideas and technologies into existing practice. Authors of
the Harvey 2002 study have proposed solutions for these barriers
including: a train-the-trainer program, which involves an educa-
tion and mentoring program for key Indigenous personnel to be-
come trainers in tobacco interventions them-selves, thus creating
a functional entity capable of upholding the intervention without
support, and another solution is to package continuing education
and training in a way which enables staff development officers and
trainers in health services to access the package as part of ongoing
development and education for new staff (Harvey 2002). Another
barrier to implementation for brief intervention is the sense of
fatalism among health staff surrounding their ability to effectively
produce change (Harvey 2002). A study by Thompson 2010 also
suggests that the smoking status of the Indigenous health care
worker may be another obstacle preventing them from providing
quit support. As such, steps need to be considered to ensure that
the attitudes and beliefs of health staff do not adversely affect im-
plementation strategies (Harvey 2002; Johnston 2010b). A factor
further complicating tobacco cessation is a reliance on the rev-
enue sales can bring to tribes, or ability to use tobacco as a cur-
rency or trade which occurs in some communities (Eichner 2005;
Baezconde-Garbanati 2007). It is important when reviewing these
barriers, to emphasize that these are complications for interven-
tions and not prohibiting factors (Eichner 2010). The health dis-
parity of Indigenous Australians has beenwell chronicled. It is now
time to ensure that methodologically rigorous investigations are
undertaken, to examine the effectiveness of tobacco interventions
and reduce the gap in Indigenous health care.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from this review suggest that Indigenous people are will-
ing to attempt smoking cessation through targeted interventions,
providing adequate resources and education are available which
are culturally appropriate. Some limited evidence exists to support
the use of behavioural interventions through culturally appropri-
ate health messages, delivered via health professionals or through
text messaging and the use of pharmacotherapies in the form of
nicotine replacement therapy and Zyban (bupropion). However
the interpretation of these results and effectiveness of these stud-
ies do need to be considered with caution due to the small sam-
ple sizes and methodological limitations. Since these studies were
completed a new smoking cessation aid specifically targeting the
19Interventions for smoking cessation in Indigenous populations (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
α-4 β-2 nicotinic receptor has become available (varenicline tar-
trate), which now requires investigation in the Indigenous popula-
tion, with close monitoring of adverse events particularly around
dreams.
More evidence is needed to clearly ascertain what interventions
and components of interventions are the most effective for smok-
ing cessation. Interventions should be of a reasonable duration and
intensity to produce an effect with consideration given to process
measures for the amount of intervention exposure an individual
is actually likely to receive. It is important to consider conduct-
ing assessments alongside any future practices to determine if an
intervention is truly effective and that investments are appropri-
ately directed. When considering strategies for intervention im-
plementation it is just as important to consider ‘who’ will deliver
the intervention. The Indigenous context must be considered at
every aspect of program execution to permit optimal uptake by
the community. Incorporating the views and recommendations
of the population is likely to enhance the effectiveness of a cam-
paign. Tailoring an intervention based on pilot work or survey data
should be considered, to ensure an appropriate intervention which
meets the requirements of the target population’s specific needs. A
multi-faceted approach which provides cessation and prevention
from various sources simultaneously and engages the community
appear more likely to increase success in the reduction and cessa-
tion of smoking.
Implications for research
There is an urgent need for research to assess interventions be-
ing funded for use in Indigenous populations, as limited evidence
exists for proven intervention effectiveness (e.g. pharmacother-
apies (including nicotine replacement therapies, bupropion and
varenicline tartrate), cognitive and behavioural therapies (CBTs)
(including counselling, support groups, self-help, seminars, mo-
tivational lectures), alternative therapies (including acupuncture,
hypnotherapy, aversion therapy), public policy (including legisla-
tive interventions, media campaigns, community interventions),
and combination therapies (including a combination of at least
two therapies from the above four categories). Studies aimed at
pregnant Indigenous women are especially vital. An assessment
of optimal tobacco cessation initiatives for Indigenous pregnant
women and the subsequent effects of tobacco use in utero and
post partum need to be urgently evaluated. Researchers need to
ensure the appropriateness of the intervention and target require-
ments specific to the population being tested; provide adequate
intervention exposure, duration and training through the use of
Indigenous project officers wherever possible to enhance the up-
take of cessation messages and select an appropriately matched
control population to compare results and collect data at both pre
and post intervention at meaningful time points (i.e. follow up of
a minimum of six months post-baseline assessment). Most impor-
tantly, be explicit and comprehensive when describing the limita-
tions and barriers of implementation, as lessons can be learnt from
past experiences which can be translated into new investigations
to improve the tobacco related health disparities which currently
exist in Indigenous populations globally.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bramley 2005a
Methods Country: New Zealand
Design: Randomised Controlled Trial
Objective/s: To determine whether a smoking cessation service using mobile phone text
messaging is as effective for M ori as non-M ori
Study Site: Done remotely via phone (not location dependent)
Programme name: STOMP study (STOp smoking by Mobile Phone)
Methods of analysis: Chi-squared analyses compared proportion quit by treatment group
with estimation of relative risk, 95% confidence intervals and two-sided p values; Fager-
ström and number of cigarettes smoked compared with analysis of covariance; Logistic
regression used for baseline effect modifiers and confounders; Participants without fol-
low-up data were assumed smoking in the primary analysis
Cluster adjustment made: None reported though not necessary for this study as subjects
are not clustered within a specific location
Participants Eligible for study (n-value): n=1705 overall population including Non-M ori
Recruited: n=176 for intervention and n=179 for control
Completed: 6 weeks n=160 for intervention and n=168 for control; 26 weeks n=80 for
intervention and n=112 for control
Age: Median (IQR - Inter-Quartile Range): Intervention 24 (19-33); Control 25 (20-
32)
Gender: Female: Intervention n=132 (75%); Control n=131 (73.2%)
Ethnicity: M ori
Socio-economic status: Income level <$15,000: Intervention n=43 (24.4%); Control n=
37 (20.7%); $15-30,000: Intervention n=83 (47.2); Control n=78 (43.6%); >$30,000:
Intervention n=49 (27.8%); Control n=63 (35.2%); Did not answer: Intervention n=1
(0.6%); Control n=1 (0.6%)
Recruitment means: M ori radio station advertising, mailing lists to M ori students
attending tertiary institutions, advertisements in a M ori student magazine, hospi-
tal staff e-mail lists, faxes to M ori health providers, via M ori smoke-free networks
and providers; Non-targeted advertising included newspapers, web-sites, magazines and
Quitline
Interventions Theoretical basis: No specific theoretical basis mentioned however text messaging as a
new communications medium is being used
Intervention description/s: Smoking cessation service using mobile phone text messaging;
Regular, personalised text messages providing smoking cessation advice, support and
distraction; Included a database of over 1000 text messages with a list of approximately
140 developed byM ori researchers related to theM ori language and included general
support messages and information on M ori customs and traditions to produce an
individualised program; A quit day was negotiated and five text messages were sent per
day for the week leading up to the quit day in addition to the four weeks following;
On the quit day free outgoing text messages also began as a means of distraction and
communicating the need for support; Six weeks after randomisation (and coinciding
with the end of the free text month) the intervention became less intensive with the
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Bramley 2005a (Continued)
number of messages reduced from five a day to three a week until the 26 week period
Control description/s: No smoking-related information though they received one text
message per fortnight reminding them to complete follow-up; If follow-up was complete
they were rewarded with a free month of text messaging; No restrictions were placed
on other smoking cessation strategies by trial participants (i.e. additional mobile phone
based services may have existed)
Duration of intervention: 26 weeks (6 months)
Intervention delivered by: Telecommunications (Vodafone customers only)
Outcomes Method of outcome collection: Baseline and follow-up data collected by mobile phone or
text messaging
Pre-specified outcome data: Prevalence of current non-smoking 6 weeks post-randomisa-
tion; secondary outcomes included self-reported non-smoking at 12 and 26 weeks
Validation: In a sub-set - Salivary cotinine
Follow-up period: Six months
Number of follow-up periods reported: Three - 6, 12 and 26 weeks
Process measures:None reported, however because each patient received the text message
directly to their mobile the implementation level would be close to 100% providing the
text messages were received
Notes Definition of point prevalence: Not smoking in the past week
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central telephone randomisation algo-
rithm used
Allocation concealment (selection bias) Low risk Central telephone randomisation with se-
quence concealment until intervention was
assigned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded to the inter-
vention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Follow-up phone calls were made by staff
who were unaware of the treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patients with missing outcome data were
assumed to be smoking; Sensitivity anal-
yses performed to assess impact of miss-
ing data; 45% attrition in the intervention
group compared to 31% for the control
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Bramley 2005a (Continued)
Selective reporting (reporting bias) Low risk No selective reporting identified; Authors
state that data were analysed following a
pre-specified analysis plan
Imbalance of outcome measures at baseline Low risk Analysis of covariance occurred
Comparanility of intervention and control
group characteristics at baseline
Low risk Baseline characteristics reported and simi-
lar for all groups - age, gender, income level
and smoking dependence/history
Protection against contamination Unclear risk Authors mention no restrictions were
placed on the use of other smoking cessa-
tion strategies i.e. trial tested the addition
of mobile phone-based services to existing
practice but no further information pro-
vided
Selective recruitment of participants Low risk n-values and methods of recruitment de-
scribed and similar across groups
Other bias High risk Incentive of one month free text messag-
ing not offered to the intervention popula-
tion; authors state some control’s may have
thought their free text month was depen-
dant on reporting quitting and may have
affected the result in favour of control
Holt 2005
Methods Country: New Zealand
Design: Randomised controlled trial; double blind, parallel group study
Objective/s: To determine the effectiveness of bupropion for smoking cessation in M
ori
Study Site: Wellington and Kapiti regions in New Zealand - single centre study
Programme name: Not provided
Methods of analysis: For the primary analysis comparisons of smoking status occurred
through normal approximation to the binomial distribution and expressed as differences
in proportions and risk ratios; Secondary analysis used generalised estimating equations
by treatment status and time of observation using an exchangeable correlation structure
to model the repeated measures; Adverse effects were calculated using the total number
of subjects allocated to a particular intervention as the denominator to calculate propor-
tions, expressed as risk ratios and confidence intervals; Exploratory analysis also occurred
with a break point at 26 weeks
Cluster adjustment made: Not applicable
Participants Eligible for study (n-value): n=300 attended public information meeting
Recruited: 2:1 randomisation occurred (two to bupropion: one to placebo); n=88 inter-
vention; n=46 control
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Holt 2005 (Continued)
Completed: n=56 intervention; n=22
Age:Mean (SD) years; Intervention: 41.7 (9.2); Control: 38.0 (11.1)
Gender:Women/total; Intervention: n=61/88; Control: n=35/46
Ethnicity: M ori
Socio-economic status: Not provided
Recruitment means: Self-recruited from advertising in local media and actively recruited
from M ori health networks
Interventions Theoretical basis:Cultural safety, reducing barriers and encouraging access through com-
munity based clinics with key involvement of M ori health providers
Intervention description/s: Bupropion (Zyban) 150mg once daily for 3 days, then 150 mg
twice daily for 7 weeks; oral course; Participants received motivational telephone calls
1 day before and 3-days after the target quit date; Follow-up visits for counselling and
data collection scheduled for 3 weeks, 7 weeks, 3 months, 6 months and 12 months after
the target quit date; Counselling topics tailored to individual participants and included
support and advice onmotivation to quit, identification of smoking triggers, diet, exercise
and role of family, friends, and work colleagues
Control description/s:Matching placebo control plus identical counselling and follow-up
schedule as the intervention
Duration of intervention: 7 week course of bupropion/placebo and eight scheduled coun-
selling sessions
Intervention delivered by: A M ori research nurse was employed to undertake this study
Outcomes Method of outcome collection: Telephone calls 1 day before and 3 days after target quit
date and scheduled clinic visits for 3 weeks, 7 weeks, 3 months, 6 months, 9 months
and 12 months
Pre-specified outcome data: Continued abstinence from smoking at 3 and 12 months;
continued abstinence from smoking at other time points and adverse events
Validation: Exhaled carbon monoxide (Smoke Check, Micro Medical)
Follow-up period: Twelve months
Number of follow-up periods reported: Six: primary: 3- and 12months; secondary: 3 weeks,
7 weeks, 6 months and 9 months
Process measures: n= 32 subjects lost to follow up by 12 months in the intervention arm
and n=24 subjects in the control arm; n=3 subjects in the intervention arm stopped
taking the medication due to a rash; No further information provided
Notes Definition of continuous abstinence: No cigarettes from the quit data and confirmed
with a negative exhaled carbon monoxide measure at each of the clinic visits
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated code
Allocation concealment (selection bias) Unclear risk Authors state a “…blinded medication
pack was dispensed…” no other informa-
tion provided
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Holt 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blinding occurred; authors state
participants were not aware which treat-
ment had been allocated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Authors state trial was double-blinded;
study teamwere not aware which treatment
had been allocated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Subjects lost to follow up were assumed
smoking
Selective reporting (reporting bias) Low risk No selective reporting identified
Imbalance of outcome measures at baseline Low risk No baseline imbalances were identified
Comparanility of intervention and control
group characteristics at baseline
Low risk Baseline characteristics for all groups were
similar and reported
Protection against contamination Low risk Unlikely that the control group received the
intervention
Selective recruitment of participants Low risk Methods of recruitment similar however re-
cruitment occurred on a 2:1 ratio for inter-
vention and control respectively
Other bias High risk Target pre-specified population n-value of
n=141 participants were not collected due
to lack of eligible subjects; Concerns over
generalisability of results - population self-
selected so were also highly motivated
31Interventions for smoking cessation in Indigenous populations (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ivers 2003
Methods Country: Australia
Design: Controlled clinical trial; pre/post design; cluster
Objective/s: The first aim of this study was to assess the patterns of use of free nico-
tine patches when offered to Indigenous people with a brief intervention for smoking
cessation. The second aim was to assess changes in smoking behaviour and attitudes
six months after access to free nicotine patches and/or a brief intervention for smoking
cessation
Study Site: Participating health clinics
Programme name: Not specified
Methods of analysis: Not described; However author’s state that ‘As a results of self-selec-
tion, the treatment groups differed on many baseline parameters… and this precludes
any direct comparison of the impact of NRT and brief intervention on smoking be-
haviour and attitudes.”
Cluster adjustment made: No
Participants Eligible for study (n-value): n=130 interviewed at baseline
Recruited: Intervention n=40; Control n=71
Completed: Intervention n=34; Control n=59
Age: 30 years or under: Intervention n=13, Control n=43; Over 30 years of age: Inter-
vention n=27, Control n=28
Gender: Intervention: female n=24, male n=16; Control: female n=27, male n=44
Ethnicity: Indigenous Australian Aboriginals
Socio-economic status: Not specified
Recruitment means: Participants were recruited from a consecutive sample of self-identi-
fied Indigenous smokers presenting to participating health centres. The sample included
some smokers nominated by a health professional
Interventions Theoretical basis:Brief intervention and advice on cessation plus nicotine patches to assist
smoking cessation; no other information provided; Transtheoretical model (stages of
change) discussed
Intervention description/s:Brief intervention for smoking cessation plus six weeks of 21mg
nicotine patches, two weeks of 14 mg patches and two weeks of 7 mg patches (total
10 weeks of treatment; patches were to be worn for 24 hours); The brief intervention
consisted of: advice on quitting, counselling on cessation, shown a flip-chart about
tobacco and provided a pamphlet
Control description/s: Brief intervention only as described above (no patches)
Duration of intervention: 10 weeks in total for course of nicotine patches; approximately
five minutes in total for brief intervention
Intervention delivered by:The researcher and a local research assistant explained the study,
administered the questionnaire and provided brief interventions for smoking cessation
Outcomes Method of outcome collection: Verbal questionnaire administered by researcher and local
research assistant
Pre-specified outcome data:Number of patches used, changes in smoking behaviour (point
prevalence), carbon monoxide breath test, attitudes to smoking, side effects experienced
and barriers to using nicotine patches
Validation: Carbon monoxide (CO) breath test
Follow-up period: Six months
Number of follow-up periods reported: One
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Ivers 2003 (Continued)
Process measures:No participant completed a full course of patches; the mean number of
patches used, as reported by participants was five patches (range 0-49 patches); Only six
people said that they had used more than seven patches, that is, 10% of the suggested
course of treatment
Notes Definition of smoking abstinence: Author did not define
Other notes:Two of the subjects claiming abstinence in the intervention arm had elevated
CO levels (10ppm) and as such were removed from analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Subjects self-selected
Allocation concealment (selection bias) High risk No allocation concealment occurred
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of subjects occurred
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nomention of blinding for outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data accounted for
within text; all subjects lost to follow-up
were assumed smoking
Selective reporting (reporting bias) Low risk No selective outcome reporting identified
Imbalance of outcome measures at baseline High risk Statistically significant differences between
intervention and control participants iden-
tified at baseline; Statistical analysis not de-
scribed
Comparanility of intervention and control
group characteristics at baseline
High risk Statistically significant differences between
intervention and control participants iden-
tified at baseline; Statistical analysis not de-
scribed
Protection against contamination Low risk Author’s state only “One participant in
the brief intervention only group had used
patches…”
Selective recruitment of participants High risk Subjects self-selected to intervention and
control groups
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Ivers 2003 (Continued)
Other bias High risk No adjustments made for potential cluster-
ing effects for the three communities; No
subjects completed a full course of patches
with the mean number used being five (out
of a potential 70 for a full course); Vali-
dation of smoking not possible in 18% of
intervention subjects and 20% of control
subjects
Johnson 1997
Methods Country: United States of America
Design: Controlled clinical trial; nested; cluster
Objective/s: Assessment of feasibility and effectiveness in the delivery of a smoking cessa-
tion intervention through health clinics, serving to urban American Indians. A primary
study goal was the implementation of a culturally appropriate adaptation to the Doctors
Helping Smokers (DHS) model
Study Site: Four urban Indian health clinics; Seattle Indian Board and Indian Health
Board of Minneapolis were the intervention sites and Spokane Urban Indian and Com-
munity Health Services and the Milwaukee Indian Health Centres were the comparison
sites
Programme name: GAINS (Give American Indians No-smoking Strategies)
Methods of analysis: Pearson’s chi-square test used to compare proportions of variations
between conditions; Student’s t-test used to compare group means of continuous vari-
ables; baseline differences adjusted for using ANCOVA; Adjusted least-square means
reported for comparison of smoking outcomes at follow-up
Cluster adjustment made: No
Participants Eligible for study (n-value): All subjects presenting for medical appointments were
screened for eligibility; No n-values were provided
Recruited: n=601 total
Completed: n=476 total; Retention rates at follow-up ? Intervention Seattle 69.3%, Min-
neapolis 83.6%; Control Milwaukee 78.3%, Spokane 85.7%
Age:Mean: Intervention 35 years, Control 36.3 years
Gender: Percent female: Intervention 67.9%, Control 59.5% (p=0.030)
Ethnicity: American Indian
Socio-economic status: Education (Intervention % vs. Control %): Junior high school or
less 6% vs. 7.7%, Some high school 28.4% vs. 29.2%, High school graduate 30.1%
vs. 31.2%, Some tech school/tech school graduate 12% vs. 8.4%, Some college 21.4%
vs. 20.8%, College graduate 2% vs. 2.7%; Current employment status (Intervention
% vs. Control %): Working full-time 19.6% vs. 31.2%, Working part-time 15.4% vs.
12%, Self-employed 1.5% vs. 3.8%, Unemployed for over 1 year 11.3% vs. 10.9%,
Unemployed for under 1 year 22.2% vs. 20.7%, Homemaker 22.2% vs. 12%, Student
6% vs. 5.3%, Retired 1.9% vs. 4.1%
Recruitment means: Urban Indian health clinics
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Johnson 1997 (Continued)
Interventions Theoretical basis: Not specified
Intervention description/s: Training provided on the Doctors Helping Smokers (DHS)
protocol. Two day training sessions were conducted with medical and laboratory staff in
each intervention site prior to enrolment; Key personnel were provided with additional
instructions on intervention techniques and enrolment procedures; The five major prin-
ciples of DHS included: screening patient smoking status and labelling charts, use of a
smoke card as a reminder to providers, clinical message-giving to discuss smoking cessa-
tion, supportive reinforcement by clinic staff, monitoring of quit progress; In addition
clinic outreach workers provided counselling in-clinic and supportive telephone calls for
smokers attempting cessation
Control description/s: Training in control sites were focused on instructions for screening
techniques of patients and record keeping; No smoking cessation training was offered in
the comparison sites however they did receive smoking cessationmaterial for distribution
to patients
Duration of intervention: Not specifically stated though intervention delivered during
doctor consult
Intervention delivered by: Doctors of the health clinics and supportive reinforcement of
clinic staff
Outcomes Method of outcome collection: 20-minute interview administered by trained clinic person-
nel
Pre-specified outcome data: Smoking history, smoking-related knowledge and behaviours,
quit intentions, alcohol use, demographics, height, weight, blood pressure, waist and hip
circumference, total cholesterol and fibrinogen
Validation: Saliva cotinine analysis
Follow-up period: Twelve months
Number of follow-up periods reported: One
Process measures: Higher proportion of intervention subjects reported attending zero
clinic visits during the study period (Seattle 24% andMinneapolis 18.9% vs. Milwaukee
27.5% and Spokane 23.2%); Receipt of study material higher in the intervention sites
with more seeing study posters in the clinic (94.5% vs. 85.6%), received study brochures
(80.7% vs. 49.7%), received self-help guide (52.8% vs. 23.9%), received phone calls
from staff regarding cessation (47.1% vs. 9.4%)
Notes Definition of smoking abstinence: Smoked even a puff of a cigarette in the past 7-days
Other notes: $25 cash incentive provided following completion of the questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation occurred, sites were se-
lected
Allocation concealment (selection bias) High risk Allocation was not concealed they were
“selected according to geographic loca-
tion, tribal diversity of the patient popula-
tion, availability of in-house primary care
providers, and patient utilisation rates.”
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Johnson 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Due to the nature of the intervention it is
not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of attempted blinding of out-
come assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Response rates were significantly lower in
Seattle (p=0.002) resulting in a higher pro-
portion of assumed-to-be-smokers as a re-
sult
Selective reporting (reporting bias) Low risk No selective reporting identified
Imbalance of outcome measures at baseline Low risk Significant baseline differences were con-
trolled as covariates in ANCOVA models
including number of cigarettes smoked per
day
Comparanility of intervention and control
group characteristics at baseline
Low risk Significant baseline differences were con-
trolled as covariates in ANCOVA models
including gender, employment status and
number of clinic visits
Protection against contamination Low risk Unlikely that the control group received the
intervention
Selective recruitment of participants Unclear risk Insufficient information to permit judge-
ment of yes or no
Other bias High risk Pre-specified study design was not possible
due to limitations in funding (from 14 sites
to 4 sites in total); some concerns over com-
parability of sites due to tribal variations at-
tending each site
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boles 2009 Control group not an Indigenous population; Follow-up period <6 months (3 months in total)
Boyle 2010 No baseline data or smoking related outcomes reported
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(Continued)
DiGiacomo 2007 No control group
Eichner 2010 Intervention not specifically aimed at smoking cessation; No smoking cessation related intervention occurred
Fu 2010 No control group
Geishirt 2005 No baseline data reported
Glasgow 1995 Unit of analysis is tribe whilst survey is conducted on tribal leaders only; No smoking related outcomes reported
Glover 2005 No control group; Follow-up period <6 months (4 months in total)
Gould 2009 No control group
Graham 2008 Not specifically targeted at Indigenous communities; Insufficient numbers of Indigenous participants for
inclusion
Grigg 2008 No control group
GrothMarnat 1996 No control group
Hayward 2007 No control group
Hensel 1995 No control group
Hiscock 2009 No control group; No baseline data reported
Hodge 1995 No control group
Horn 2005 Follow-up period <6 months (3 months in total)
Ivers 2005 No control group
Ivers 2006 No control group for comparison of survey data, only comparison through tobacco vendors
Laugesen 2000 No baseline data collected
Lichtenstein 1995 No smoking related outcome data reported
Panaretto 2009 No control group
Panaretto 2010 No control group
Patten 2010 Follow-up period <6 months (108 days in total)
Whittaker 2011 Results not reported separately for the Indigenous population
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Characteristics of ongoing studies [ordered by study ID]
Atkinson 2008
Trial name or title BOABS Study (Be Our Ally Beat Smoking)
Methods Country: Australia
Design: Randomised Controlled Trial; Block stratification by study site
Objective/Aim: Prevention
Study site: Patients visiting primary health care services
Other: Sequence generation through Computer-generated randomization table created by computer software;
Allocation concealment through research assistant at the trial site required to contact the central administration
site, which holds the allocation schedule. They will then allocate subjects to intervention or control group
based on the computer-generated randomization schedule
Participants Target sample size: n=360
Age: 16 years minimum
Gender: Both males and females
Ethnicity: Aboriginal and/or Torres Strait Islander
Inclusion/exclusion criteria: Inclusion criteria: Current smoker, Aboriginal/Torres Strait Islander, regular client
of the health service, considering quitting smoking soon (within the next 30 days); Exclusion criteria: Unable
to provide informed consent, health condition that would prohibit completion of trial, unlikely to be available
for follow up at 12 months
Interventions Intervention description:Multi-dimensional smoking cessation intervention; Individualised smoking cessation
plan including regular personal contact and counselling (approximately 12-14 individual sessions per subject)
; In addition, monthly group sessions and support to assist access to existing smoking cessation, health and
other services will also be offered
Control description: Best practice regional clinic based smoking cessation program based on the Kimberley
Smoking Cessation Protocol
Duration of intervention: 12 months
Outcomes Pre-specified outcomes in protocol: 12 month smoking abstinence by urine cotinine levels and self-report; self-
report for proportion of subjects reporting reductions in number of cigarettes smoked each week; self-report
using health questionnaire of subject health status
Validation: Urinary cotinine levels
Follow-up period: 12 months
Number of intended follow-up periods: Two, 6- and 12 months
Other: Blinding of outcome assessors to occur
Starting date 08/12/2008
Contact information Primary contact: Dr David Atkinson; PO BOX 1377, Broome, WA 6725, Australia; TEL: +61 8 91936043;
FAX: +61 8 91922500; david.atkinson@uwa.edu.au
Secondary contact: Dr Julia Marley; PO BOX 1377, Broome, WA 6725, Australia; TEL: +61 8 91936043;
FAX: +61 8 91922500; julia.marley@uwa.edu.au
Notes
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Choi 2010
Trial name or title ANBL (All Nations Breath of Life)
Methods Country: United States of America
Design: Randomized controlled trial
Objective/Aim: To examine the efficacy of a culturally-tailored smoking cessation program for American
Indian/Native Alaskan
Study site: Two sites in the Midwest (Kansas and Oklahoma)
Participants Target sample size: n=448 smokers with n=28 groups per site, containing n=8 smokers per group
Age: 18-years and older
Gender: Both
Ethnicity: American Indian and Native Alaskan
Inclusion/exclusion criteria: Inclusion criteria: Age 18 years and older, have a home address and telephone
number, willing to participate in all study components, willing to be followed for 6 months, smoked at
least 100 cigarettes in their lifetime, current smoker, American Indian or Native Alaskan; Exclusion criteria:
Planning to leave the state within next 24 months, pregnant or breast feeding or planning to become pregnant
in the next 4 months, medically ineligible after screening
Interventions Intervention description: All subjects will be offered pharmacotherapy (e.g. varenicline, bupropion or nicotine
replacement therapy) plus the culturally-tailored ANBL program; The ANBL program consists of in-person
group sessions and individual telephone calls
Control description: All subjects will be offered pharmacotherapy (e.g. varenicline, bupropion or nicotine
replacement therapy) plus a non-tailored accompanying program with targeted counselling delivered by non-
American Indian counsellors
Duration of intervention: Not specified
Outcomes Pre-specified outcomes in protocol: Smoking status and continuous abstinence, number of quit attempts, utili-
sation of smoking cessation pharmacotherapy, number of cigarettes smoked
Validation: None reported
Follow-up period: 12 months
Number of intended follow-up periods: Two, 6- and 12 months
Starting date September 2010
Contact information Dr Won Choi, wchoi@kumc.edu , University of Kansas Medical Centre, Kansas City, Kansas, United States,
66160, TEL: 913-588-4742
Notes
Eades 2009
Trial name or title Not specified
Methods Country: Australia
Design: Randomized controlled trial
Objective/Aim: To test the effect of a multifaceted high intensity intervention that is culturally specific and
incorporates advice, support and nicotine replacement therapy for smoking cessation in pregnant Indigenous
women; This intervention is designed to improve the extent to which staff in Indigenous primary health care
clinics are able to support pregnant women who are smokers to quit during their pregnancy
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Eades 2009 (Continued)
Study site:Clinics for pregnant women, actual setting not described; Controls seen in usual general practitioner
clinical health care setting
Other: No blinding intended
Participants Target sample size: n=270
Age: 16-50 years
Gender: Females only
Ethnicity: Aboriginal Australians
Inclusion/exclusion criteria: Inclusion criteria: Pregnant women attending antenatal care before 20 weeks’
gestation; Exclusion criteria: Major mental illness or chemical dependency other than tobacco or alcohol
Interventions Intervention description:Multifaceted tailored intervention which includes culturally specific advice and sup-
port for Indigenous women; Evidence based communication and nicotine replacement therapy will be used
after 2 failed quit attempts (smokers < 25 cigarettes per day can use 2mg gum up to 24 times per day; smokers
>25 cigarettes per day can use 4mg gum up to 24 times per day); The gum is prescribed as needed for up to
12 weeks
Control description:Usual clinical care with brief general practitioner as well as clinic health care provider quit
advice
Duration of intervention:Minimum of 2 visits at the clinic, within 5- and 14 days following the visit at which
the subject agrees to quit smoking; Specific duration of advice and support services not described; nicotine
replacement therapy prescribed for up to 12 weeks
Outcomes Pre-specified outcomes in protocol: Self-reported and cotinine validated smoking cessation
Validation: Cotinine validation
Follow-up period: Baseline recruit must be before 20 weeks gestation; Follow-up between 36 to 40 weeks
gestation and 6 months post-partum
Number of intended follow-up periods: Two, 36 to 40 weeks gestation and 6 months post-partum
Starting date 01/11/2005; Follow up completed
Contact information Professor Sandra Eades; Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria
2004, Australia; TEL: +61 3 8532 1535; FAX: +61 3 8532 1100; sandra.eades@bakeridi.edu.au
Notes
Johnston 2010a
Trial name or title Not specified
Methods Country: Australia and New Zealand
Design: Randomized controlled trial; Stratification using permuted blocks by country and infant age
Objective/Aim: To reduce respiratory illness in Indigenous infants
Study site: Darwin City and the Greater Darwin area in the Northern Territory, Australia and within the
Counties Manukau District Health Board region, Manukau City, New Zealand; Indigenous families residing
in these two geographical areas were recruited with Indigenous newborn infants as the sampling units
Other: Allocation concealment will occur using central randomization through a computer with potential
participants assigned a unique registration number allocated by a central computer following details submitted
on a web-based form; The number will be used to identify each randomized participant once consent is
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Johnston 2010a (Continued)
obtained thus permitting blinding of people assessing the outcomes and analysing the results/data; Sequence
generation will occur by computer, stratified for country
Participants Target sample size: n=420
Age: For mothers/caregivers 16 years or older
Gender:Mothers/caregivers of infants
Ethnicity: Aboriginal Australians, M ori
Inclusion/exclusion criteria: Inclusion criteria for mother/caregiver: Indigenous (defined by maternal self-iden-
tification), 16 years or older, currently smokes or infant lives in a household with at least one other person
smokes (defined as smoking at least weekly), plans to reside permanently with the infant in Darwin or Greater
Darwin areas of Australia or within the Counties Manukau District Health Board region, Manukau, New
Zealand, signed written consent to participate received, English or M ori speaking
Interventions Intervention description: Family-centred tobacco control program aimed at providing education about the
health effects of Environmental Tobacco Smoke (ETS) and behavioural ‘coaching’ techniques to helpmothers
reduce the infant’s exposure to ETS and identify mothers and other household members motivation to quit
smoking and deliver culturally appropriate smoking cessation counselling and treatment options (e.g. nicotine
replacement therapy) as required
Control description:Usual care through community health providers including routine visits to maternal and
child health providers; checking of developmental progress and well being of the infant; mothers receive
messages about smoking cessation and ETS exposure in their homes during visits as part of general health
promotion
Duration of intervention: Three face-to-face home visits conducted over the first three months of the infant’s
life
Outcomes Pre-specified outcomes in protocol: Mother/caregiver’s self-report of smoking cessation: defined as not smoking
a single cigarette (not even a puff ) in the preceding seven days by the mother/caregiver; Prolonged abstinence
(e.g. quit for 3 months at 4 months follow up; quit for 9 months and 12 month follow up); Other outcomes
relating to infant ETS exposure and health are also included
Validation: None reported
Follow-up period: 12 months
Number of intended follow-up periods: Two; 4 months, and 12 months; Baseline is when infant aged 5 weeks
Starting date 09/11/2009
Contact information Dr Vanessa Johnston; Menzies School of Health Research; PO BOX 41096, Casuarina, Northern Territory
0811, Australia; TEL: +61 (0)8 8922 7968, FAX: +61 (0)8 8927 5187; vanessa.johnston@menzies.edu.au
Notes Smoking cessation outcomes as assessed for this review are a secondary outcome of this investigation
Maddison 2010
Trial name or title Fit2Quit Study
Methods Country: New Zealand
Design: Randomized controlled trial; Stratified by study centre, sex and ethnicity
Objective/Aim: To determine the effects of a home and community-based exercise intervention (Fit2Quit) on
smoking abstinence at six months follow up when used as an adjunct to usual care, being telephone smoking
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Maddison 2010 (Continued)
cessation counselling and nicotine replacement therapy
Study site: Callers to Quitline in the greater Auckland and Waikato areas
Other: Sequence generation through a computer central randomization service
Participants Target sample size: n=1400 (n=700 per arm)
Age: 18-years or older
Gender: Both
Ethnicity:
At least 25% will be M ori
Inclusion/exclusion criteria: Inclusion criteria: 18 years or older, resident in greater Auckland orWaikato areas of
New Zealand interested in quitting, want to be physically active, smoke their first cigarette within 30-minutes
of waking, contact via telephone possible, able to provide written informed consent; Exclusion criteria Stroke
or heart related condition or severe angina in the last two weeks, enrolled in competing smoking cessation
programs, have a medical condition which limits their ability to exercise safely, currently participating in an
exercise program or participating in greater than 150 minutes of physical activity per week
Interventions Intervention description: Exercise intervention (prescription and behavioural support) in addition to usual care
of telephone support through Quitline and subsidised nicotine replacement therapy prescribed free of charge
by the national Quitline
Control description: Usual care alone (i.e. combination of telephone support and subsidised nicotine replace-
ment therapy prescribed free of charge)
Duration of intervention: Minimum of 10 contacts (face-to-face) over 6 months for home-based exercise
program plus counselling and referral to community-based activities and programs; Goal for individuals to
participate in a minimum of 30 minutes of moderate-vigorous aerobic-based exercise
Outcomes Pre-specified outcomes in protocol: Seven-day point prevalence of smoking abstinence validated using salivary
cotinine, 6-month continuous abstinence, BMI (body mass index), cardio-respiratory fitness, physical activity
levels, cost effectiveness
Validation: Salivary cotinine
Follow-up period: 6 months
Number of intended follow-up periods: Three; 2-, 3- and 6 months
Starting date 01/02/2010
Contact information Primary contact: Dr Ralph Madison, Clinical Trials Research Unit, University of Auckland, Private Bag
92019, Auckland 1142, New Zealand; TEL: +64 9 373 7599 (extension 84718); FAX: +64 9 373 1710; r.
maddison@ctru.auckland.ac.nz
Secondary contact: Dr Vaughan Roberts, Clinical Trials Research Unit, University of Auckland, Private Bag
92019, Auckland 1142, New Zealand; v.roberts@ctru.auckland.ac.nz
Notes M ori population approximately 25% of overall sample
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Smith 2010
Trial name or title Menominee Smoking Cessation Clinical Trial
Methods Country: United States of America
Design: Randomized controlled trial
Objective/Aim:To evaluate the effectiveness of a culturally-tailored smoking cessation treatment for American
Indian smokers, compared to a standardised (non-culturally-tailored) evidence-based cessation treatment
Study site:Menominee Tribal Clinic serving Menominee and other American Indian patients
Participants Target sample size: n=150
Age: 18 years and older
Gender: Both
Ethnicity: American Indians, specifically the Menominee
Inclusion/exclusion criteria: Inclusion criteria: At least 18 years of age, smoking cigarettes, eligible to receive
health care services at theMenominee Tribal Clinic (i.e. must be an enrolledmember of a federally-recognised
American Indian Tribe), primary care provider is at theMenominee Tribal Clinic, must be medically able and
willing to take varenicline; Exclusion criteria: End-stage renal disease with haemodialysis, any prior suicide
attempts, current or recent (past 12-month) suicidal ideation, currently pregnant or breastfeeding, unwilling
to use appropriate methods of birth control while taking study medication for 1-month after discontinuing
study medication, primary care provider determines that the individual should not take varenicline
Interventions Intervention description: 12 weeks open-label varenicline tartrate use plus smoking cessation counselling con-
sisting of four sessions (1 via phone and 3 in person); Counselling consists of standard treatment counselling
plus culturally-appropriate treatments such as discussion of the history of sacred/traditional use of tobacco
(honouring and respecting native traditions) and how it differs from use of commercial tobacco use (harming
health), custom booklet on smoking and smoking cessation tailored to Menominee and other American
Indian smokers, participants are encouraged to make their own traditional tobacco pouch (symbol of long
life)
Control description: Same as above for varenicline and number of counselling sessions, however standard
treatment counselling is used based on recommendations in the 2008 U.S. Public Health Service Guideline
(Treating Use and Dependence); Topics include preparing to quit, nicotine addiction, coping with stressors
and challenging situations, coping with withdrawal symptoms, seeking support and relapse prevention
Duration of intervention: 12 weeks open label varenicline tartrate use, counselling consists of four sessions,
one in-person pre-quit counselling, one via a phone call and the remaining two in-person counselling sessions
Outcomes Pre-specified outcomes in protocol: 7-day point prevalence of smoking abstinence, self-reported abstinence and
carbon monoxide validated abstinence at 3- and 6-months
Validation: Exhaled carbon monoxide
Follow-up period: 6 months
Number of intended follow-up periods: Two, 3- and 6months
Starting date February 2010
Contact information Primary contact: Dr Steven Smith, University of Wisconsin, Madison, USA
Secondary contact: Jodi Fossum, jodif@mtclinic.net , TEL: 715-799-5754
Notes
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Walker 2011
Trial name or title RELIQ - Reduced Levels of nicotine in cigarettes to Increase Quitting
Methods Country: New Zealand
Design: Randomised controlled trial; Stratified by gender, ethnicity and level of nicotine dependence
Objective/Aim: Determine the combined effect of nicotine-free cigarettes with nicotine replacement therapy
(immediately post quitting) on long-term quit rates (6-months). Secondary aim is to determine if such an
intervention is cost effective and acceptable
Study site: Recruitment through the national telephone-based Quitline service in New Zealand
Other: Sequence generation will occur via a computer, with stratification
Participants Target sample size: n=1410
Age: 18 years or older
Gender: Both
Ethnicity: 25% M ori
Inclusion/exclusion criteria: Inclusion criteria: Smokers from throughout New Zealand who want to stop
smoking, at least 18-years of age, have their first cigarette within 30-minutes of waking, able to provide verbal
consent and have a telephone; Exclusion criteria: Pregnant women and women breastfeeding, current users of
nicotine replacement therapy, current client of another smoking cessation program (e.g. Txt2Quit and NRT
Online), current user of other pharmacotherapy for smoking cessation, use only non-cigarette tobacco (e.g.
pipes, cigars), have had a myocardial infarction within the last two weeks, have had angina, severe cardiac
arrhythmia or strike in acute phase within the last two weeks
Interventions Intervention description: Subjects in the intervention will be asked to stop smoking nicotine-containing
cigarettes on a chosen quit day and smoke ad libitum nicotine-free cigarettes for six-weeks; Subjects will
also receive nicotine replacement therapy in the form of patches, gum and/or lozenges (as recommended by
Quitline) for eight weeks; Plus Quitline counselling
Control description: Subjects will receive nicotine replacement therapy in the form of patches, gum and/or
lozenges (as recommended by Quitline) for eight weeks; Plus Quitline counselling
Duration of intervention: Intervention and control arms will receive eight weeks of nicotine replacement
therapy, whilst the intervention only arm will receive an additional six weeks of nicotine-free cigarettes (Quest
3)
Outcomes Pre-specified outcomes in protocol: Proportion of subjects who stopped smoking in the proceeding 7-days (7-day
point prevalence) at the 6 month follow up; continuous abstinence, number of cigarettes currently smoked
per day; physical signs and symptoms associated with withdrawal, self-rated chances of quitting, reduced
smoking, cost information, use of NRT and non-NRT, adverse events, concomitant medication and alcohol
use and abuse
Validation: None reported
Follow-up period: 6-months
Number of intended follow-up periods: Four: 3- and 6 weeks and 3- and 6 months
Other: Blinding of trial steering committee, management committee and other team members from the
Clinical Trials Research Unit (with the exception of the project co-ordinator and Quitline research manager)
will remain blinded to treatment allocation
Starting date 01/04/2009
Contact information DrNatalie KWalker; Clinical Trials ResearchUnit, School of Population Health, TheUniversity of Auckland,
Private Bag 92019, Auckland, 1142, New Zealand; n.walker@ctru.auckland.ac.nz
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Walker 2011 (Continued)
Notes M ori population approximately 25% of overall sample
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D A T A A N D A N A L Y S E S
Comparison 1. Intervention versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Smoking cessation 4 1081 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.03, 1.98]
1.1 Point prevalence 3 947 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.95, 1.91]
1.2 Continuous abstinence 1 134 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.79, 4.98]
2 Attitudes - readiness to quit 1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.82, 3.30]
3 Smoking cessation - Sensitivity
analysis
3 989 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.95, 1.85]
3.1 Point prevalence 2 855 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.86, 1.76]
3.2 Continuous abstinence 1 134 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.79, 4.98]
Analysis 1.1. Comparison 1 Intervention versus control, Outcome 1 Smoking cessation.
Review: Interventions for smoking cessation in Indigenous populations
Comparison: 1 Intervention versus control
Outcome: 1 Smoking cessation
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Point prevalence
Bramley 2005a 38/176 33/179 61.7 % 1.17 [ 0.77, 1.78 ]
Ivers 2003 5/33 1/59 1.4 % 8.94 [ 1.09, 73.32 ]
Johnson 1997 18/250 13/250 24.5 % 1.38 [ 0.69, 2.76 ]
Subtotal (95% CI) 459 488 87.6 % 1.35 [ 0.95, 1.91 ]
Total events: 61 (Experimental), 47 (Control)
Heterogeneity: Chi2 = 3.55, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.70 (P = 0.089)
2 Continuous abstinence
Holt 2005 19/88 5/46 12.4 % 1.99 [ 0.79, 4.98 ]
Subtotal (95% CI) 88 46 12.4 % 1.99 [ 0.79, 4.98 ]
Total events: 19 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
0.02 0.1 1 10 50
Favours control Favours experimental
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 547 534 100.0 % 1.43 [ 1.03, 1.98 ]
Total events: 80 (Experimental), 52 (Control)
Heterogeneity: Chi2 = 4.29, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
0.02 0.1 1 10 50
Favours control Favours experimental
Analysis 1.2. Comparison 1 Intervention versus control, Outcome 2 Attitudes - readiness to quit.
Review: Interventions for smoking cessation in Indigenous populations
Comparison: 1 Intervention versus control
Outcome: 2 Attitudes - readiness to quit
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ivers 2003 11/33 12/59 100.0 % 1.64 [ 0.82, 3.30 ]
Total (95% CI) 33 59 100.0 % 1.64 [ 0.82, 3.30 ]
Total events: 11 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours experimental Favours control
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Analysis 1.3. Comparison 1 Intervention versus control, Outcome 3 Smoking cessation - Sensitivity analysis.
Review: Interventions for smoking cessation in Indigenous populations
Comparison: 1 Intervention versus control
Outcome: 3 Smoking cessation - Sensitivity analysis
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Point prevalence
Bramley 2005a 38/176 33/179 62.6 % 1.17 [ 0.77, 1.78 ]
Johnson 1997 18/250 13/250 24.9 % 1.38 [ 0.69, 2.76 ]
Subtotal (95% CI) 426 429 87.4 % 1.23 [ 0.86, 1.76 ]
Total events: 56 (Experimental), 46 (Control)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Continuous abstinence
Holt 2005 19/88 5/46 12.6 % 1.99 [ 0.79, 4.98 ]
Subtotal (95% CI) 88 46 12.6 % 1.99 [ 0.79, 4.98 ]
Total events: 19 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Total (95% CI) 514 475 100.0 % 1.33 [ 0.95, 1.85 ]
Total events: 75 (Experimental), 51 (Control)
Heterogeneity: Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.096)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours experimental
A D D I T I O N A L T A B L E S
Table 1. Narrative synthesis of intervention effectiveness
Study ID/sub-headings: Detailed synthesis of intervention effectiveness:
Bramley 2005a
Smoking behaviour
Point prevalence: M ori participants in the treatment group were more likely to report having
stopped smoking at 6 weeks than those in the control group with 26.1% quit compared to
11.2% (RR: 2.34, 95% CI: 1.44 - 3.79); Smoking cessation rates at 12 and 26 weeks reported
rates remaining high in the intervention group (21.6%) but increased in the control group
(18.4%)
Intermediate outcome data None reported
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Table 1. Narrative synthesis of intervention effectiveness (Continued)
Holt 2005
Smoking behaviour
The rates of continued abstinence in the bupropion vs. placebo groups were 44.3% and 17.
4% (risk ratio 2.54 (95%CI 1.30 to 5.00)) at 3 months, and 21.6% and 10.9% (risk ratio
1.99 (95% CI 0.79 to 5.00)) at 12 months for intervention and control groups respectively.
Reported risk ratios (95% confidence intervals) for the remaining follow-up periods were: 1.
00 (0.84 to 1.20) at 3 days; 1.47 (1.06 to 2.05) at 3 weeks; 1.39 (0.93 to 2.10) at 7 weeks; 2.
72 (1.12 to 6.61) at 26 weeks; 2.51 (1.03 to 6.14) at 39 weeks. The model based approach
with a break point in the abstinence-time slope at 26 weeks favoured the intervention, with a
risk ratio of 2.44 (95%CI 1.22 to 4.88).
Intermediate outcome data Adverse events: Authors report most side effects as mild and self-limiting; Subjects taking
bupropion were more likely to have insomnia (26% vs. 9%; risk ratio 3.0 (95% CI 1.1 to 8.
2) over the placebo arm. Three subjects taking bupropion discontinued use due to a rash
Ivers 2003
Smoking behaviour
Point prevalence: six of those in the nicotine patch group reported they had quit whilst one
member of the brief intervention only group had quit. However two participants in the
nicotine patch group recorded an elevated CO level (10ppm) and as such there data were not
used
Intermediate outcome data Adverse events: Twenty-nine per cent of subjects using patches experienced bad dreams, 21%
pruritis, 4% nausea, 7% palpitations or shakiness and 7% tiredness. 93% said that the patches
stayed stuck on all or most of the time; mortality: One subject in the intervention arm died of
causes unrelated to the use of patches; Attitudes - readiness to quit: no significant changes in
readiness to quit for intervention or control groups (Fishers’ Exact p=1.0 and 0.21 respectively)
. 38% of smokers in the intervention group and 29% in the control group were less ready
to quit after trying patches than they had been at the baseline visit; costs of interventions:
nicotine patches costs approximately $32-35 in addition to freight costs for a week’s supply,
in comparison a week’s supply of cigarettes for a pack a day smoker is $46-74. It appears that
there were other factors apart from the costs of nicotine patches that prevented smokers from
using NRT as an aid to quitting, which might have included a widespread perception that
smoking was normal behaviour
Johnson 1997
Smoking behaviour
At 1 year followup 7.1%of intervention subjects reported being abstinent compared to control
subjects with 4.9%. However when only the validated quits are included the percentages
drop to 6.7% and 6.8% for intervention and control groups respectively. Furthermore when
subjects missing from follow up are counted as smokers the point prevalence for validated
quits is reduced to 5.3%
Intermediate outcome data None reported
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Risk of bias categories were updated to include four additional fields: imbalances of outcome measures at baseline; comparability of
intervention and control group characteristics at baseline; protection against contamination and selective recruitment of participants.
In addition, the classification categories for risk of bias have been amended from ’yes’, ’no’ and ’unclear’ to ’high risk’, ’low risk’ and
’unclear risk’.
The search strategy was amended with removal of the key word ’indig*’, which was replaced with ’Indigenous*’ as the former was over
sensitive.
Examination of the review by an Indigenous (Aboriginal) Australian was added to assess applicability, acceptability and content.
Review Manager software version changed from 5.0 to 5.1
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